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ABSTRACT 
Alzheimer's disease (AD) is characterized by progressive dementia and 
accumulation of a cleavage product of the amyloid precursor protein, amyloid-~ (A~) 
peptide, in the brain. Several lines of evidence suggest that soluble, oligomeric 
intermediates of A~ are primarily responsible for synaptic dysfunction and the cognitive 
deficit observed in AD. The cellular prion protein (PrPc), a cell surface glycoprotein 
involved in transmissible spongiform encephalopathies, was previously identified as a 
high affinity receptor for A~ oligomers. It has been suggested that binding of A~ 
oligomers to PrPc transduces the synaptotoxic events seen in AD. The two reported 
binding sites of A~ oligomers are located on the unstructured N-terminal tail ofPrPc. 
We show here that the soluble physiological cleavage fragment ofPrPc, Nl, was 
necessary and sufficient for binding A~ oligomers. This binding interaction was 
Vll 
influenced by positively charged residues in the two binding sites and is dependent on the 
length ofthe sequence between them. Importantly, the addition of synthetic Nl peptide 
suppressed A~ oligomer toxicity in cultured murine hippocampal neurons and in a mouse 
model of A~-induced memory dysfunction. Collectively, these data suggest that Nl, or 
small peptides derived from it, could be potent inhibitors of A~ oligomer toxicity by 
targeting A~ oligomers and represent an entirely new class of therapeutic agents for AD. 
To directly target PrPc as a toxicity receptor, in silica screening and molecular dynamics 
were used to generate small molecule ligands. We screened these ligands using 
biochemical and biophysical assays to identify high affinity ligands for PrPc that block 
the binding of A~ oligomers. We found one compound, called DS26 that bound to PrPc 
with sub-micromolar affinity. Further, DS26 inhibited A~-dependent suppression of 
long-term potentiation in mouse hippocampal slices. Interestingly, we show that DS26 
operated by an unexpected allosteric mechanism in which ligand binding to a site in the 
structured C-terminal half ofPrPc induced an intramolecular interaction with theN-
terminal tail, thereby preventing A~ binding. Together, these data demonstrate that 
pharmacologically targeting PrPc can suppress A~ toxicity. Additionally, this study 
clarifies previous conflicting studies regarding the role ofPrPc in AD. 
Vlll 
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Chapter 1. Introduction 
1.1 Alzheimer's Disease 
a. Alzheimer's Disease Overview. 
Alzheimer's disease (AD) is the most common form of dementia with five million 
patients in the United States and 35 million worldwide [1]. The best known risk factor 
for developing AD is age. After age 65, the risk of AD doubles every five years. AD is 
the fifth largest cause of death in the elderly, and is one ofthe most expensive diseases 
[2] . The Medicare cost of treating an AD patient is three times higher than the treatment 
of a non-AD patient. In 2012, over $200 billion was spent on healthcare, long-term care, 
and hospice services for AD patients. These statistics will continue to rise as the 
population of the United States ages. By 2050, it is expected that a new AD diagnosis 
will occur every 33 seconds, affecting over 11 million Americans [2]. If effective 
therapies are not developed quickly, the disease will continue to have a devastating 
medical and economic impact on society. 
The first case of AD was observed in 1901 by the German physician, Alois 
Alzheimer. His report was based on observations in the case of Auguste Deter. The 
patient was described as having reduced comprehension, memory, aphasia, 
disorientation, unpredictable behavior, paranoia, auditory hallucinations, and pronounced 
psychosocial impairment [3]. After the patient's death in 1906, histologic staining 
revealed abnormal protein deposits in the brain (Figure 1 ). These deposits are now 
referred to as amyloid plaques and neurofibrillary tangles. 
1 
b. Alzheimer 's Disease Symptoms and Pathology. 
AD is a neurodegenerative disease that leads to progressive cognitive impairment 
and death. Symptoms start as mild, cognitive impairment with memory loss, and 
difficulty with concentration [4, 5]. As the disease progresses, symptoms extend to 
behavioral changes, reduced problem solving abilities, and mood swings [6]. In 
advanced AD cases, assistance is required for basic tasks, long term memory becomes 
impaired, and language and motor skills decline [ 6]. AD is always fatal with an average 
time of 8 years from diagnosis to death. Fewer than 3% of patients survive 14 years after 
AD diagnosis [7]. 
A clinical hallmark of AD is deposits of amyloid plaques and neurofibrillary 
tangles in the brain [6]. The amyloid plaques are made up of the amyloid beta (A~) 
peptide, a cleavage fragment of the amyloid precursor protein (APP), which can 
spontaneously oligomerize and form insoluble aggregates [8]. Neurofibrillary tangles 
consist of hyper-phosphorylated tau proteins [9]. Tau is normally associated with the 
stabilization of microtubules. Hyper-phosphorylated tau can self-assemble into tangles. 
The presence of A~ oligomers, amyloid plaques, and neurofibrillary tangles are 
associated with retraction of dendritic spines, synaptic dysfunction, and ultimately, 
neuronal death. AD brains show significant atrophy in the hippocampus, cerebral cortex, 
and ventricular enlargement [10]. Changes in these regions can affect memory 
formation, intelligence, judgment, language, and behavior. 
2 
c. Alzheimer's Disease Mechanisms. 
There have been three major proposed mechanisms to explain the effects seen in 
AD: the cholinergic hypothesis [11], the amyloid hypothesis [12, 13], and the tau 
hypothesis [14]. The cholinergic hypothesis proposes that AD is caused by reduced 
synthesis of the neurotransmitter acetylcholine (ACh) [11]. The amyloid and tau 
hypotheses address how tau and A~ can mediate the effects seen in AD [ 12, 13] [ 15]. 
The cholinergic hypothesis is the oldest of these three hypotheses, dating back to 
the mid-1970s [11]. Support for this idea was based in early observations that AD patient 
brains had neocortical deficits in choline acetyltransferase, the enzyme that synthesizes 
ACh. ACh is a neurotransmitter in both the peripheral and central nervous systems, and 
studies have suggested that ACh may play a role in learning and memory [16]. Further 
reports of reduced choline uptake, ACh release, and the loss of cholinergic neurons from 
the basal forebrain confirmed a substantial presynaptic cholinergic deficit in AD brains 
[17]. The cholinergic hypothesis has been the basis for several AD pharmaceuticals 
including tacrine, donepezil, rivastigmine and galantamine; these agents all inhibit the 
enzyme, acetylcholinesterase, which converts ACh into the inactive metabolites, choline 
and acetate, found in the synaptic cleft. (reviewed in [11 , 18, 19]) 
The amyloid hypothesis was proposed by Hardy and Allsop in 1991 [12, 13] since 
amyloid plaque deposits and neurofibrillary tangles in the brain were the main 
histopathologic characteristics observed in cases of AD. In this model, deposits of the 
A~ peptide are fundamental to AD because A~ initiates a sequence of events that 
3 
ultimately leads to dementia in AD patients (Figure 2). Tau hyper-phosphorylation and 
neurofibrillary tangle formation are downstream of A~ accumulation. Several lines of 
evidence support this hypothesis. The A~ peptide is a cleavage product of the amyloid 
precursor protein (APP). The gene that encodes APP is located on chromosome 21 [20]. 
Individuals with Down Syndrome (trisomy 21) carry three copies of APP and usually 
develop severe AD symptoms by the age of 40 [7, 8]. The extra copy of the APP gene 
may increase the amount of A~ in the brain, causing a more aggressive disease 
phenotype. 
Evidence for the amyloid hypothesis also comes from several genetic studies. 
One ofthe largest risk factors for AD is a specific isoform of apolipoprotein E (ApoE). 
ApoE is involved in the clearance and degradation of soluble A~ [21, 22]. There are 
three isoforms of ApoE as defined by two residues: ApoE2 (Cys112, Cys158), ApoE3 
(Cys 112, Arg158), and Apo E4 (Arg112, Arg158) [23]. The ApoE4 isomer has reduced 
efficiency in A~ clearance. At least one ApoE4 allele was found in 80% of familial and 
64% of sporadic AD patients [24]. Mutations in the APP gene can also alter the amount 
of A~ produced. One example is the APP Swedish mutation, a double mutation in APP 
ofK670N I M671L associated with early onset AD [25]. Cells expressing this mutant 
produce 3-6 times more A~ compared to normal APP [26]. Another mutation, APP 
A673T, was found to reduce the amount of A~ peptide released by 40%. This mutation 
was found to be protective against AD and cognitive decline in a population study of 
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1,795 Icelanders [27]. These genetic studies show a correlation between the levels of A~ 
peptide in the brain and AD. 
Further support for the amyloid hypothesis comes from studies demonstrating that 
the A~ peptide can spontaneously aggregate to form dirners, oligomers, protofibrils, and 
fibrils [28]. Initial AD research focused on the toxicity of fibrils and amyloid plaques 
[29]. However, the formation of plaques in AD patient brains does not always correlate 
with disease progression [30]. This suggests that other forms of A~ may be a toxic agent 
in AD. Several studies have demonstrated that oligomeric A~, not monomers or fibrils , 
can cause synaptic dysfunction in AD. One study showed that cell-conditioned media 
containing A~ oligomers inhibited hippocampal long term potentiation (L TP) in rats [31]. 
Another study found that nonfibrillar, amyloid beta-derived, diffusible ligands (ADDLs) 
were able to kill neurons at nanomolar concentrations, as well as inhibit LTP [32]. In 
patients with AD, the levels of soluble A~ oligomers correlate with synaptic loss and 
cognitive decline [33]. Research aimed at determining the exact size of the soluble A~ 
oligomers involved in synaptic dysfunction is ongoing. Studies have suggested that 
dimers [34] , trimers [35] , A~* 56 (a soluble 56 kDa A~ assembly)[30], and higher 
molecular weight species are the toxic conformation [34]. 
In the amyloid hypothesis, the accumulation of A~ in the brain is thought to occur 
before hyper-phosphorylation of tau and the formation of neurofibrillary tangles. One 
--
study in mice found that A~-induced neurite degeneration required expression of either 
human or mouse tau. In tau knockout animals, there was no neurotoxicity [36]. In 
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another study, treatment of A~ oligomers induced hyper-phosphorylation of tau leading 
to cytoskeleton disruption and neurite degeneration [37]. These reports support the 
amyloid hypothesis in that the accumulation of A~ occurs before tau hyper-
phosphorylation and neurofibrillary tangle formation. 
In the tau hypothesis, the tau protein initiates the AD disease cascade. Tau, a 
microtubule associated protein (MAP) found mainly in the neurons of the central nervous 
system (CNS), is involved in the assembly and stability of axon microtubules. Hyper-
phosphorylation of tau inhibits the ability of the protein to interact and stabilize 
microtubules [38] . Phosphorylated tau proteins can spontaneously form neurofibrillary 
tangles and sequester unphosphorylated, normal tau proteins, leading to microtubule 
dissociation [9] . Impaired axonal transport from cytoskeleton disorganization can lead to 
synaptic dysfunction. The tau hypothesis is supported by several lines of evidence. The 
formation of plaques in AD patient brains does not always correlate with disease 
progression [30] . Conversely, the formation of neurofibrillary tangles [15] and the 
detection of hyper-phosphorylated tau species in the cerebrospinal fluid (CSF) is 
associated with AD progression [39]. Additionally, targeting tau therapeutically with 
drugs that reduce tau filaments has been shown to reduce cognitive impairment [40]. 
d. Current Therapies for Alzheimer 's Disease. 
AD is a fatal , neurodegenerative disease with no known cure. There are several 
drugs used to treat the symptoms of the disease in the United States; these include 
acetylcholinesterase inhibitors and an N-Methyl-D-aspartate (NMDA) receptor 
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antagonist. However, none of these available therapies have been shown to prolong 
lifespan or halt disease progression. If effective drugs against AD are not developed, the 
disease will continue to have a devastating impact on society, both medically and 
economically. 
e. Cholinesterase Inhibitors. 
The cholinergic hypothesis suggests that reduced ACh levels from the loss of 
cholinergic neurons could be directly responsible for the impairment of learning and 
memory seen in AD. The reduced levels of ACh could be overcome by 
pharmacologically targeting acetylcholinesterases, the enzymes responsible for 
converting ACh into the inactive metabolites, choline and acetate. Reducing activity 
levels of acetylcholinesterases in the synaptic cleft could increase ACh concentrations 
thus, leading to improved memory and cognition. Currently, there are four approved 
acetylcholinesterase inhibitors: tacrine, donepezil, rivastigrnine, and galantamine. These 
drugs have been shown to improve cognition in some patients with early stages of AD, 
but they do not halt AD progression. [ 41]. 
f Reducing Af3 levels in Brain. 
The amyloid hypothesis suggests that A~ induces the toxicity and synaptic 
dysfunction seen in AD. In this model, lowering the levels of AP could rescue learning 
and memory impairment. A~ levels can be pharmacologically targeted by reducing A~ 
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production from APP and/or increasing the clearance of the soluble A~ peptide. An 
additional pharmacological strategy for AD could be to inhibit peptide aggregation. 
The A~ peptide is a cleavage product of APP. APP is a transmembrane protein 
suggested to play a role in cellular adhesion, metal homeostasis, and neuronal function 
[42, 43]. There are 8 isoforms of APP, reproduced from alternative splicing, that range in 
size from 670 to 770 residues [ 44]. APP695 is the most common form found in neuronal 
tissues [45]. A~ release begins with APP cleavage between Met 671 and Asp 672 by the 
beta site APP cleaving enzyme (BACE1) [46]. The C-terminal fragment of APP then 
undergoes an additional cleavage by y-secretase. The y-secretase is a complex comprised 
ofpresenilin (PS), presenilin enhancer (Pen-2), nicastrin (Net), and anterior pharynx 
defective (Aph-1) proteins [ 4 7]. PS serves as the active site of the enzyme complex and 
cleaves APP between residues, 710-715. This secondary cleavage of APP releases a 
soluble peptide that is between 39-42 amino acids in length [46]. APP can also undergo 
non-amyloidogenic processing in which APP is cleaved by a-secretase, generating a 
soluble N-terminal peptide (sAPPa) and non-amyloidogenic C-terminal fragment (C83). 
C83 can be further cleaved by y-secretase, generating a non-amyloidogenic peptide (P3) 
which is not involved in AD (Figure 1-3). The focus ofthis manuscript will be on A~ 
containing residues 1-42 and referred to hereafter as A~. The exact site of A~ peptide 
production is unknown and could take place at cell surfaces, endosomes, or lysosomes 
[48]. 
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Another therapeutic approach to lower A~ levels in the brain is through secretase 
modulators that reduce APP processing into the A~ peptide. Targeting the first cleavage 
step with ~-secretase inhibitors has been shown to lower A~ levels in the brains of AD 
transgenic mice [ 49]. However, ~-secretase has additional targets besides APP including 
neuregulin-1 (NRG 1 ), a neuronal transmembrane protein involved in growth signaling 
[50]. Nonspecific inhibition of ~-secretase could be detrimental for cell signaling 
pathways. The only APP-specific ~-secretase inhibitor that has passed Phase I clinical 
trials is CTS-21166 from CoMentis (CoMentis Inc., San Francisco, CA). In transgenic 
AD mice, treatment with CTS-21166 resulted in A~ levels that were decreased by 35% 
without affecting NRG 1 processing [51]. Similar to ~-secretase inhibitors, drugs that 
block the activity of y-secretase could also lower A~ levels. This has been demonstrated 
with a known y-secretase inhibitor, DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester) [52]. However, similar to ~-secretase, y-secretase also 
targets additional proteins besides APP, such as Notch. Notch is a membrane-bound 
protein involved in signaling and development. Pharmaceutical compounds, such as 
Begacestat (Pfizer, New York, NY), have been developed to specifically target y-
secretase cleavage of APP [53]. 
In addition to investigating the reduction of A~ peptide production with secretase 
inhibitors, researchers have also examined ways to increase A~ clearance as a potential 
AD therapy. Immunotherapy has been suggested as a promising therapeutic approach to 
increase A~ clearance. Schenk et al. demonstrated that active immunization of young 
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AD mice with synthetic A~42 prevented the development of ~-amyloid plaque formation, 
neuritic dystrophy, and astrogliosis, and also reduced AD-like neuropathologies in older 
animals. However, others have shown that active immunization of mice with a heavy 
burden of amyloid plaque deposits is not effective [54]. 
The use of immunotherapy to prevent A~ toxicity is based on the several 
proposed mechanisms of action for antibodies, i.e. antibodies can 1) alter the soluble 
equilibrium between monomeric A~ and plaques, 2) increase A~ phagocytosis, or 3) 
prevent A~ aggregation. In the soluble equilibrium method, antibodies bind and 
sequester the A~ peptide. In one study, passive peripheral immunization with an anti-A~ 
antibody, m266, resulted in a 1,000-fold increase in plasma A~ and reduction of A~ 
plaques in the brain [55]. These data suggest that the levels of A~ in the plasma and the 
CNS are at equilibrium, and therapeutic antibodies would not need to cross the blood-
brain barrier. In the phagocytosis mechanism, the antibody must be present in the CNS 
to allow interaction with A~ plaques and guide microglial cells. Bard et al. demonstrated 
that treatment with anti-A~ antibody, 10D5, triggered microglial cells to clear plaques 
through Fe receptor-mediated phagocytosis [56]. Finally, A~ toxicity could be prevented 
using antibodies that target early amyloid seeds and prevent further aggregation of A~ 
into large oligomers and plaques [57]. 
Several anti-A~ antibodies are being developed as potential treatments for AD. 
One antibody, 3D6, was shown to reduce amyloid plaques in an AD mouse model [56, 
58]. However, Bapineuzumab (Pfizer, New York, NY and Johnson & Johnson, New 
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Brunswick, NJ), the humanized equivalent to 3D6, has had little success in AD patients. 
A recent clinical Phase III trial with bapineuzumab revealed little cognitive improvement 
and no reduction of the amyloid plaques in treated patients compared to placebo controls 
[59]. Additionally, in patients using bapineuzumab, there was an increase in side effects 
including edema and hemorrhages [60]. The poor results ofbapineuzumab in clinical 
trials could be due to late timing of the treatment or targeted selection of the treatment 
groups. Animal studies have suggested that immunotherapy is most effective when 
started before there is significant amyloid deposition [54]; patients in the early to mid-
stages of AD already have significant A~ levels [54]. This suggests that bapineuzumab 
might be more effective at earlier stages of the disease. 
Recently, DeMattos et al. suggested that immunotherapy against A~ would be 
more effective using antibodies that specifically target A~ plaques. They found that the 
antibody, mE8, which binds specifically to pyroglutamate A~ and not soluble A~, was 
able to strongly decrease the amount of pre-existing plaques in AD mouse models. 
Treatment with mE8, before mice developed amyloid plaques, did not prevent plaque 
formation [61]. It has been suggested that the soluble fraction of A~ could be saturating 
antibodies, like bapineuzumab, before they can reach target areas. Thus, a plaque-
specific antibody, such as mE8, would not be affected by soluble A~ and would be able 
to target and reduce plaque burden [62]. Additionally, studies have shown that 
concentrations of monomeric A~ and fibril forms of the protein are in equilibrium [55, 
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63]. Therefore, a therapeutic combination of these anti-A~ antibodies, 3D6 and mE8, 
could prove to be a powerful treatment option by attacking both soluble A~ and plaques. 
While the exact mechanism of toxicity in AD is not known, many studies suggest 
a role for soluble A~ oligomers. Several pharmacological compounds have been 
developed that bind A~ and block aggregation of the protein into oligomers and fibrils. 
One example, scyllo-inositol (ELND005), a specific stereoisomer of inositol, has been 
reported to inhibit A~ aggregation, lower A~ plaques, and reverse memory impairment in 
AD mice [64]. Scyllo-inositol clinical trials are currently underway. 
g. Additional Therapies for Alzheimer's Disease. 
In addition to changes in the levels of ACh, there have been reports of increased 
glutamate levels in AD [ 65]. Glutamate is an excitatory neurotransmitter that can 
activate NMDA receptors. NMDA receptors are a class of voltage-gated ion channels 
involved in memory, synaptic plasticity, and long term potentiation. An excess of 
glutamate can overexcite NMDA receptors leading to neurotoxicity. However, complete 
inhibition of the NMDA receptor signaling would be detrimental in the brain. One AD 
drug, memantine, acts as a NMDA receptor antagonist. Memantine was selected as a 
non-competitive inhibitor with low affinity and rapid dissociation. These 
pharmacological properties preserve the physiological function ofNMDA receptors 
while reducing the adverse effects of excess glutamate. In patients, memantine has been 
shown to provide a moderate decrease in symptoms [ 66]. 
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Several publications have identified inflammation, oxidative stress, and vascular 
dysfunction as having a role in AD progression [67]. Treatment with non-steroidal anti-
inflammatory drugs (NSAIDs) such as sulphide, indomethacin, and ibuprofen, have been 
shown to lower the risk of AD and reduce symptoms in patients with AD [68]. NSAIDs 
have also been reported to alter A~ levels by reducing the activity of y-secretase [ 69]. 
The antioxidant, Vitamin E, has also been suggested to be beneficial in patients with AD 
by reducing the effects of A~-induced oxidative stress [70]. 
1.2 Prion Diseases 
a. Cellular Prion Protein (PrPc). 
The cellular prion protein (PrPc) is a glycosylphosphatidylinositol-anchored (GPI) 
glycoprotein found on the cell membrane [71] . The physiological function ofPrPc is 
currently unknown. PrPc is ubiquitously expressed in tissues throughout the body; 
however the highest levels are found in the CNS [72]. Homologous proteins can be 
found in a wide range of species ranging from mammals to zebrafish [73]. 
b. Structure of Pr Pc. 
Mouse PrP is a 254 residue protein with sequence homology to human PrP. (The 
PrPc used in the research presented in this thesis refers to mouse PrP). NMR and X-ray 
crystallography studies have identified two contrasting regions on PrPc, the structured C-
terminal end and flexible N-terminus. The folded C-terminal domain (residues 120-230) 
contains three a-helices (residues 143-152, 168-191, and 200-226) and two~ strands 
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(residues 121-129 and 152-168). The unstructured N-terminus has no observable 
secondary structure as determined from NMR or CD analyses (Figure 4) [74, 75]. 
There are a number of structural regions believed to be important in the biology of 
PrPc. The extreme N-terminus (residues 1-22) contains a weak signal peptide that 
promotes co-translational import into the endoplasmic reticulum (ER). After entry into 
the ER, the signal sequence is cleaved. TheN-terminus on the mature protein begins 
with a polybasic region (residues 23-31) that is believed to be involved in many activities 
including clathrin-mediated endoycytosis, binding to glycosaminoglycans, translocation 
of peptides across the plasma membrane, targeting to lipid rafts, and binding of the 
infectious form ofPrPc, denoted PrPsc [76-80]. TheN-terminal half ofthe protein also 
contains a series of octapeptide repeats, i.e. five copies ofP(H/Q)GGG(G)WGQ (residues 
51-90). These histidine containing repeats are known to bind Cu2+, as well as other 
bivalent metals. Binding of metals can impart some secondary structure to the region and 
induce endocytosis from the cell membrane [81, 82]. Expansion ofthis region is linked 
to a familial form ofprion disease in humans [83, 84]. The central region ofPrPc is 
composed of a series of highly positively-charged amino acids (residues 95-111) 
followed by a hydrophobic stretch (residues 111-134 ). Antibodies targeting the charged 
residues in this region have been suggested to promote apoptosis in the hippocampus and 
cerebellum of mice [85]. However, this effect has been disputed [86]. The hydrophobic 
residues are highly conserved and act as a membrane-spanning domain in transmembrane 
forms of the protein. Deletions of this hydrophobic central region produce a severe, 
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neonatal toxic phenotype in transgenic mice [87, 88]. The structured C-terminal domain 
ofPrP contains two N-linked oligosaccharide chains, covalently bound at Asn 180 and 
Asn 196, and a disulfide bridge between Cys 178 and Cys 214 [89]. The extreme C-
terminal region (residues 231-254) is cleaved after attachment ofthe 
glycophosphatidylinositol (GPI) anchor. 
c. PrPc Physiological Cleavage. 
PrPc is the target of proteolytic cleavage under normal physiological conditions 
[90]. Interactions between the hydrophobic region ofPrPc and the zinc-dependent 
metalloproteases, ADAM (a disintergrin and metalloprotease) 10 or 17, can generate at 
least four separate protein fragments [91]. Cleavage has been reported to occur in the 
secretory pathway of the cell between PrP residues 110/111-12 and 90/91 [92]. The 
resulting fragments are named N1 /Cl and N2/C2, respectively (Figure 5). Both C1 and 
C2 protein fragments remain anchored to the outer leaflet of the plasma membrane 
through their GPI anchor, whereas N1/N2 are released as soluble fragments into the 
extracellular space. Soluble N1 can be readily detected in mouse brain homogenate 
(Figure 6). 
Similar to PrPc, the biological role of the N/C fragments are unknown. There are 
very few published studies focusing on the role of PrPc cleavage fragments. These 
reports have mainly examined the role of the C-terminal products, C1 and C2. Both C1 
and C2 are abundantly produced in normal brains. It was found that the levels of C2 
increased in brains infected with a prion disease, Creutzfeldt-Jakob disease (CJD) [90]. 
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However, the role of the additional C2 in prion disease remains unclear. In a separate 
study, the C1 fragment was shown in cell models to be pro-apoptotic via a caspase 3/p53 
mechanism [93]. Conversely, the C2 fragment had no effect in this model. Interestingly, 
a previous study in our lab has shown that transgenic mice expressing only the C 1 
fragment are not susceptible to prion diseases. Mice co-expressing the C 1 fragment and 
full length PrPc show a significant delay in the onset of prion disease symptoms [91]. 
This suggests that C1 can act in a dominant negative function, and may have a 
neuroprotective effect in cells. 
Studying the role of the N1 and N2 prion fragments might be limited by the weak 
signal sequence ofPrPc. Previous studies have shown that the structured C-terminus of 
PrPc is required for successful translocation of the peptide into the ER [94]. Constructs 
with a deletion of the C-terminus (residues 112-254) show poor secretion and high 
amounts of proteasome-dependent degradation of the expressed protein. This effect can 
be overcome by using a stronger secretion signal or attaching an a-helically structured 
protein to the C-terminal end ofthe truncated prion protein [95]. This has limited the 
ability to generate N1 constructs for investigation of protein expression in cells and mice. 
Presumably, it is for this reason that the few reported studies ofN1 have used 
recombinantly-generated proteins [96-99]. 
Using synthetic Nl, Guillot-Sestier and colleagues have shown that Nl is 
neuroprotective against staurosporine induced apoptosis by reducing p53-mediated cell 
death [98]. Nl was also shown to protect against the cytotoxic effects of A~ monomers 
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and oligomers [97] . The authors explained this effect by the ability ofN1 to activate 
intracellular cell survival mechanisms involving the Akt/p53 pathway. There may be a 
more direct means by which N1 could block A~ toxicity and further discussion of this 
topic will follow. 
d. Biological Roles for PrPc. 
Despite the discovery of PrP several decades ago, researchers have yet to find, or 
agree upon, a precise function for PrPc. Confusing matters more, PrP transgenic 
knockout mice show no strong disease phenotypes and have normal life spans [100]. 
This observation suggests that PrPc may be redundant in mice or have a nonessential 
role. Several proteins have been identified as PrPc binders either by co-
immunoprecipitation, crosslinking, or yeast two-hybrid screen experiments (Table 1-1) 
[101]. PrP may play possible roles in cell signaling [102-105] , neuroprotection [106] , 
synaptic maintenance [107-11 0] , cell adhesion [111], oxidative stress protection [112-
114], or cell survival/death pathways [115-119] . However, many questions remain about 
the relevance of these binding interactions as a few of the proposed binding partners are 
located in separate compartmentalized areas of the cell away from PrPc. 
e. Prion Disease (PrPc). 
Although little is known about its normal function, PrPc is associated with a 
family of rare, progressive, neurodegenerative disorders. Prion diseases, or transmissible 
spongiform encephalopathies (TSEs ), can be inherited, sporadic, or infectious, and affect 
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both humans (Creutzfeldt-Jakob Disease, Variant Creutzfeldt-Jakob Disease, Gerstmann-
Straussler-Scheinker Syndrome, Fatal Familial Insomnia, and Kuru) and animals (Bovine 
Spongiform Encephalopathy, Chronic Wasting Disease, Scrapie). The disease involves 
the conversion and misfolding ofPrPc into an infectious_ and toxi_c form, PrPsc_ Once 
PrPsc is formed, it can serve as a template to convert additional molecules of PrPc into 
PrPsc. Prion diseases, and the infectious agent PrPsC, differ from traditional infectious 
diseases in that genetic material (DNA and RNA) is not required for the spread of the 
infection [71]. It is unclear how PrPsc causes toxicity. Attempts to identify whether loss 
of normal PrPc function, or gain of toxic function in PrPsc, have been largely 
inconclusive (reviewed [120]). 
Presumably, due to the heterogeneous nature ofPrPsc, there is very little structural 
information published on PrPsc compared to PrPc. CD experiments have shown PrPsc 
has an increased ~-sheet content compared to the mostly a-helical PrPc. The increase in 
~-sheet content could be a main driving factor in the oligomerization and aggregation of 
the protein. PrPsc is also described as detergent insoluble and protease resistant (Figure 
7) [121-123]. 
1.3 PrPc, A Receptor for AP Oligomers 
a. Identification of PrPc as Receptor for A{3 Oligomers. 
Nanomolar concentrations of soluble A~ oligomers have been shown to cause 
adverse effects in AD models including inhibition of long-term potentiation (L TP), 
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dendritic spine retraction, and impairment rodent spatial memory [31, 124, 125]. These 
data, combined with the observation that AB oligomers bind to hippocampal neurons in a 
dose dependent manner with saturation, lead Lauren et al. to hypothesize that there must 
be a single, high affinity receptor for AB oligomers expressed on the surface of cells. To 
examine this possibility, a eDNA library screen of 225,000 constructs was used to test the 
binding of biotinylated AB oligomers to COS-7 cells. The authors found one of their 
positive constructs, PrPc, bound AB oligomers with nanomolar affinity. However, fresh 
preparations of monomeric AB did not bind. Additionally, the authors found that PrPc 
was required for AB oligomer-mediated inhibition ofhippocampal LTP [126]. 
Subsequently, Gimbel et al. used various genetic mouse models to examine the 
role ofPrPc in AD. Using a transgenic mouse with the APPswe/PSen1AE9 mutations, 
the authors found that ablation ofthe PrPctransgene rescues 5-HT axonal degeneration, 
loss of synaptic markers, early death, and deficits in spatial learning and memory [127]. 
This study confirmed the earlier in vitro work and demonstrated that PrPc is required for 
memory deficits in AD transgenic mice. Other groups have reported similar PrPc 
dependence in AD. Specifically, it has been reported that targeting the PrPc/AB oligomer 
interaction with antibodies prevented LTP inhibition and learning deficits in mice [128-
131]. 
b. Identification of A{3 Oligomer Binding Sites on PrPc. 
PrPc has been identified as a high affinity receptor for AB oligomers with a KD of 
92 nM. Using a cell-based binding assay, deletion mutants and an antibody screen 
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identified the first binding site for A~ oligomers. N-terminal truncations L132-106 and 
L132-121 failed to bind A~ oligomers. Binding was unaffected by deletions ofthe acta-
repeat regions (residues 51-90) and ofthe central hydrophobic region (residues 105-125). 
Antibodies 6D 11 (which recognizes resides 93-1 09) also inhibited the interaction. 
Together, the results indicate that A~ oligomers bind to residues 95-105, a highly 
positively charged region in the flexible N-terminal region ofPrPc [126]. 
The binding of A~ oligomers to PrPc was confirmed and further explored using 
surface plasmon resonance (SPR) and electron paramagnetic resonance (EPR) 
spectroscopy. In this study, Chen et al. observed a dose-dependent binding of A~ 
oligomers to recombinant PrPc and calculated a KD of71 nM. Several N-terminal PrP 
deletion mutants were tested using SPR for binding of A~ oligomers. Mutations in the 
extreme N-terminus of the polybasic region significantly decreased the binding 
interaction. This study concluded that a secondary site, residues 23-27, on PrPc is 
required for the binding of A~ oligomers [132] to PrPc. 
Two additional studies have confirmed the high affinity binding interaction 
between PrPc and A~ oligomers. Using SPR, Balducci et a!. demonstrated binding of A~ 
oligomers to PrPc captured from mouse brains [133]. Other reports have used ELISA to 
measure the binding interaction. Freir et al. confirmed the binding and demonstrated that 
the binding interaction could be modulated with antibodies against PrPc. Both ICSM18 
(residues 131-151) and ICSM35 (residues 95-105) blocked the interaction of A~ 
oligomers with PrPc [130]. The modulation of A~ oligomers binding to PrPc by ICSM18 
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could arise from either a structural rearrangement of the globular domain, which is 
transmitted to theN-terminus, or from the close spatial distances of the A~ oligomers 
binding site and the target ofiCSM18, helix 1. 
c. PrPc as Toxic Receptor for Af3 Oligomers and Other Aggregates. 
At least one study has demonstrated that PrPc can bind other ~-sheet rich 
aggregated proteins [134]. Rosenberger et al. demonstrated that A~ oligomers, misfolded 
forms ofPrP, Sup35 (a yeast prion), and synthetic ~-sheet rich artificial peptides bind to 
theN-terminus ofPrPc and increase toxicity in SH-SY5Y cells. Additionally, the authors 
found that an NMDA receptor antagonist inhibits the toxic signaling, suggesting a 
connection between PrPc and the NMDA receptor in AD pathology [134]. 
NMDA receptors have long been thought to have an important role in AD. The 
presence of A~ oligomers has been demonstrated to cause alterations in the distribution 
and endocytosis ofNMDA receptor in cells [135]. Further, NMDA receptors are 
required for dendritic spine retraction following A~ oligomers treatment [125]. Urn et al. 
and Larson et al. have speculated that the Fyn kinase could be a possible connection 
between PrPc and the NMDA receptor in A~ oligomer signaling. Fyn has been 
previously shown to phosphorylate NMDA receptor subunits, NR2A and NR2B [136]. 
Overexpression of Fyn in AD transgenic mice led to increased impairment of spatial 
memory [137]. Further, Fyn and PrPc both localized to lipid rafts in the plasma 
membrane [138]. U1m et al. demonstrated that both PrPc and Fyn are required for A~ 
induced dendritic spine loss. The authors proposed a model in which Fyn phosphorylates 
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NMDA receptor subunits leading to alterations in calcium signaling and eventual 
redistribution of the NMDA receptors [139]. Larson eta!. validated that PrPc, A~ 
oligomers, and Fyn form a complex on neuronal dendritic spines and that A~ oligomers-
induced Fyn activation can be inhibited with an anti-PrP antibody 6D11 [140]. Their 
report suggests that the A~/PrP/Fyn complex can hyper-phosphorylate tau leading to 
synaptic dysfunction. Together these results suggest a pathway connecting A~ oligomers 
and PrPc to downstream signaling pathways (See Figure 8). 
d. Controversy on Role of PrPc in Alzheimer 's Disease. 
While several lines of evidence suggest that PrPc plays a role in AD, some studies 
have questioned this possibility. Bladucci eta!. confirmed that A~ bound to PrPc with 
high affinity using SPR. However, in their study, PrPc was not required for A~ oligomer 
memory impairment. In their AD model, mice were given acute intracerebroventricular 
injections of A~ oligomers and memory impairment was measured using a novel object 
recognition test [133]. Additional conflicting reports have been published using LTP as a 
read out. Calella eta!. used several genetic mouse models of AD [141] and Kessels eta!. 
investigated organotypic hippocampal slices infected with an APP-expressing virus 
[142]. Both of these studies failed to show a PrPc-dependence on A~ oligomer-induced 
suppression of L TP. 
The differences in reports on PrPc -dependence of A~ oligomer toxicity in AD 
could arise from several factors. First, the authors of the conflicting studies used 
different models of AD. All models of AD are artificial as wild-type mice do not develop 
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AD. Second, the authors could be describing phenomena in which certain AD models 
require PrPc for toxicity and others do not. Third, the time point of measurements 
differed between reports. Additionally, there are discrepancies about the source of A~ 
oligomers. Sources of A~ oligomers range from synthetic peptides to brain extracted 
natural oligomers. It is also possible that some models of AD take additional time to 
develop observable symptoms that are PrPc dependent. 
1.4 Objective of this Thesis 
Alzheimer's Disease (AD) is the most common form of dementia in people over 
65 years old. Currently, there is no cure for the disease, and the underlying molecular 
pathways are poorly understood. AD is associated with progressive dementia and 
accumulation of neurofibrillary tau tangles and amyloid-~ (A~) plaques. A~ oligomers 
are thought to be responsible for the synaptic dysfunction underlying the cognitive 
decline in AD. However, the mechanism by which these A~ oligomers impart their 
neurotoxic effects has yet to be fully defined [143, 144]. 
A novel candidate has recently emerged as a receptor for the A~ oligomers: the 
cellular form of the prion protein (PrPc). PrPc has been largely studied in the context of a 
completely different group of neurodegenerative disorders known as prion diseases. PrPc 
is a membrane glycoprotein expressed at the neuronal surface and has been shown to bind 
A~ oligomers with high affinity [145]. Other data suggests that PrPc could play a role in 
A~ oligomer-induced synaptotoxicity, although this evidence is still controversial. 
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Notably, the two putative binding sites for A~ oligomers identified in PrPc are 
both encompassed within the flexible, N-terminal tail ofPrPc. This region can be 
released after an alpha-secretase cleavage as part of the normal physiological processing 
ofPrPc, to produce a soluble fragment called PNl. 
The objective of this research is to investigate the role ofPrPc and its fragments 
in AD. We hypothesize that Nl has a therapeutic role in the brain by selectively binding 
soluble, A~ oligomers, reducing their fibril growth, and preventing interactions with their 
cellular receptor(s), thus reducing the cytotoxic effects of A~ in AD. To address the role 
of full length PrP in AD, we postulate that pharmacologically preventing the PrP- A~ 
oligomer binding interaction can inhibit the toxicity of A~ oligomers. 
My specific aims are as follows: 
Aim 1: Characterize PrP I A~ oligomer interaction 
a) Validate the binding of A~ oligomers to full length PrP and Nl and determine 
binding parameters using IP assays and SPR measurements. 
b) Examine the effect ofNI on synthetic A~ oligomerization and fibril growth using 
thioflavin T (ThT) fluorescence. 
c) Determine the minimally required binding regions in PrP-Nl for A~ oligomers 
using by mutating the binding sites and the length between binding sites. 
d) Examine ifNI binding to A~ oligomers blocks the toxicity in AD models. 
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Aim 2: Characterize the binding of small molecules to PrPc 
a) Validate the binding of small chemical molecules identified during an in silica 
screen to PrPc 
b) Determine the location of the small molecule binding pocket. 
c) Examine the effect of the small molecule binding to PrPc on the binding of A~ 
oligomers to PrPc 
· d) Determine the mechanism of inhibition for the small molecule 
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Table 1. PrPc binding proteins. 
Protein 
14-3-3 
Aldolase C 
Bcl-2 
Caveolin-1 
CK2 
GFAP 
Glypican-1 
Grb2 
hnRNP 
A2/B1 
HOXA1 
Hsp60 
LRP 
LRP1 
Mahogunin 
MPG 
N-CAM 
Neuroglobin 
NR2D 
NRAGE 
Nrf2 
Pintl 
PLK3 
STI-1 
Synapsin 1b 
Tau 
TREK-1 
Tubulin 
Function Method 
Bind signaling proteins Pull-down, Overlay, Co-IP 
Glycolytic enzyme Overlay 
A -apoptotic regulator Y2H, Co-IP, Affinity 
Caveolar coat Co-IP 
Protein kinase (cell division and Pull-down, SPR, 
signal transduction) Overlay, Co-IP 
Intermediate filament Pull-down, Overlay, Co-IP 
Heparan sulfate proteoglycan Co-IP 
Signal transduction (adaptor Y2H, Co-IP, Co-
protein) fractionation 
pre-mRNA processing Overlay 
Transcription Factor for Microarray, Co-IP Embryonic Development 
Chaperone Y2H 
Extracellular matrix interactions Y2H 
Receptor-mediated Endocytosis Co-IP 
E3-ligase Pull-down, affmity 
DNA Repair Enzyme Microarray, Co-IP 
Cell adhesion Cross-linking 
Hemoprotein Affinity 
NMDA receptor subunit Co-IP 
Activator of apoptosis Pull-down, Y2H, Co-IP 
Transcription factor for Bacteriophage 
antioxidant response expression library 
Unknown Y2H, Co-IP 
Protein kinase (cell cycle) Microarray, Co-IP 
Heat shock protein Complementary hydropathy, Co-IP 
Synaptic vesicle trafficking Y2H, Co-IP, Co-fractionation 
Stabilizes microtubules Pull-down, Co-IP 
Two-pore K + channel Y2H, Co-IP 
Pull-down, Co-IP, 
Microtubule subunit Co-fractionation, Cross-linking, 
Affinity 
Westergard et al. 2007 [101] 
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Localization 
Cytoplasm 
Cytoplasm 
Cytoplasm 
Plasma membrane 
Cytoplasm 
Cytoplasm 
Plasma membrane 
Cytoplasm 
Nucleus/Cytoplasm 
Nucleus 
Cytoplasm 
Cytoplasm, Plasma 
membrane? 
Plasma membrane 
Cytoplasm 
Nucleus 
Plasma membrane 
Cytoplasm 
Plasma membrane 
Cytoplasm 
Cytoplasm/Nucleus 
Cytoplasm 
Cytoplasm, Plasma 
membrane 
Cytoplasm, Plasma 
membrane? 
Cytoplasm 
Cytoplasm 
Plasma membrane 
Cytoplasm 
Figure 1. Amyloid plaques and neurofibrillary tangles in the cerebral cortex of 
Auguste Deter. 
(A) Light microscopic view of ~-amyloid plaques and neurofibrillary tangles in the 
cerebral cortex ofthe first reported case of AD, Auguste Deter. (B) Enlargement of an 
amyloid plaque. (C) Enlargement of neurofibrillary tangles. Reproduced with permission 
from Graeber et all Histopathology and APOE genotype of the first Alzheimer disease 
patient, Auguste D. Neurogenetics, 1998. 1 (3) : p. 223-8. [146]. 
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Figure 2. The amyloid cascade hypothesis. 
This schematic represents the proposed sequence of events in AD. The curved, violet 
arrow indicates that A~ oligomers may directly injure the synapses and neurites of brain 
neurons, in addition to activating microglia and astrocytes. Reproduced with permission 
from Hardy et al. The amyloid hypothesis of Alzheimer's disease: progress and problems 
on the road to therapeutics. Science, 2002. 297(5580) : p . 353-6. [144] 
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Figure 3. Amyloidogenic and non-amyloidogenic APP processing. 
In the amyloidogenic pathway, APP is cleaved by ~-secretase, generating a soluble N-
terminal fragment (sAPP~) and membrane bound C-terminal fragment (C99). The C-
terminal fragment is further cleaved by y-secretase, generating the A~ peptide. In non-
amyloidogenic processing, APP is cleaved by a-secretase which generates the soluble N-
terminal fragment (sAPPa) and a non-amyloidogenic C-terminal fragment of 83 residues 
(C83). The C-terminal fragment can be further cleaved by y-secretase releasing the non-
amyloidogenic peptide (P3), which is not involved in AD. Reproduced with permission 
from Spuchet et al. New insights in the amyloid-Beta interaction with mitochondria. J 
Aging Res, 2012. 2012: p . 324968. [147] 
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Figure 4. Structure of the cellular prion protein, PrPc. 
(A) Schematic illustration of the functional domains ofPrPc. The unstructured, flexible 
N-terminus contains a signal secretion sequence (residues 1-22, black), polybasic region 
(residues 23-27, green), histidine-containing octapeptide repeats (residues 51-90, gray), 
positively charged region (residues 95-111, cyan), and hydrophobic domain (HD, 
residues 111-130). The globular C-terminus contains two ~-strands (residues 127-129, 
yellow; and 166-168, purple) and three a-helices (residues 143-152, blue; 171-191, 
orange; and 199-221 , red). PrP is anchored to the cell membrane through a GPI anchor 
attached to residue 230. (B) Three-dimensional structure ofPrPc. Reproduced with 
permission from Biasini et al. Prion protein at the crossroads of physiology and disease. 
Trends Neurosci, 2012. 35(2): p. 92-103. [120] 
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Figure 5. PrPc undergoes a physiological c)eavage. 
Model showing two cleavage fragments ofPrPc, Nl and Cl, after cleavage by a-
secretase. Soluble Nl is released into the intercellular space and Cl remains bound to the 
plasma membrane via its GPI anchor. 
35 
GPI Anchor 
PrPc 
179 2142301 
/ 
NlLII:=J 
23 111 112 
36 
Figure 6. Nl is present in the soluble fraction of mouse brain homogenate. 
Mouse brains expressing PrP (C57/B6), PrP (Tga +10) , PrP (Tga +!+) , and PrP-C 1 
transgenic mice were homogenated in PBS without detergent. Samples were 
immunoprecipitated with 100B3, an anti-PrP antibody that recognizes residues 27-31, 
and immunoblotted with 6Dll, an anti-PrP antibody that reacts with residues 27-31. A 
12 kDa protein band corresponding to N1 (PrP residues 23-111) can be seen in C57/B6, 
Tga +10, Tga +I+ and Tga +I+ mouse brains, but not in the C1 brains. 
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Figure 7. Comparison ofPrPc and PrP8c. 
(A) The predicted structure of PrPc (90-231) shows three a-helices and two ~-strands. 
(B) A model ofPrPsc showing increased ~-sheet content. Below each panel is a 
comparison of the primary distinguishing features ofPrPc and PrPsc. Reproduced with 
permission from Prusiner, S.B. , Shattuck lecture--neurodegenerative diseases and prions. 
N Eng! J Med, 2001. 344(20): p . 1516-26. [148] 
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Figure 8. Models of PrPc Fyn activation. 
(A) Proposed model ofFyn activation [139]. Binding of AJ3 oligomers to PrPc leads to 
Fyn kinase activation. Fyn phosphorylates NMDA receptor subunits leading to 
alterations in calcium signaling and eventual redistribution of the receptor. Reproduced 
with permission from Urn et al. Alzheimer amyloid-beta oligomer bound to postsynaptic 
prion protein activates Fyn to impair neurons. Nat Neurosci, 2012. 15(9): p . 1227-35. 
(B) Proposed model ofFyn activation [140]. The PrPc/AB complex forms a complex 
with Fyn and Cav-1 leading to activation of Fyn kinase. Fyn hyper-phosphorylates tau 
leading to aberrant accumulation of tau and synaptic dysfunction. Reproduced with 
permission from Larson, et al. The complex PrP(c)-Fyn couples human oligomeric Abeta 
with pathological tau changes in Alzheimer's disease. J Neurosci, 2012. 32(47) : p. 
16857-71a 
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Chapter 2. N-terminal fragment of the prion protein binds to amyloid-beta 
oligomers and inhibits neurotoxicity in vivo. 
(I' ext and Figures 1, 4, 5, 6, 7, 8, 10, 11 were published in the Journal of Biological 
Chemistry on March 151h, 2013 volume 288, pages 7857-7866 [99]) . 
2.1 Summary 
A hallmark of Alzheimer's disease (AD) is the accumulation of the amyloid-~ 
(A~) peptide in the brain. Considerable evidence suggests that soluble A~ oligomers are 
responsible for the synaptic dysfunction and cognitive deficit observed in AD. However, 
the mechanism by which these oligomers exert their neurotoxic effect remains unknown. 
Recently, it has been reported that A~ oligomers bind to the cellular prion protein (PrPc) 
with high affmity. Here, we show that N1, the main physiological cleavage fragment of 
PrPc, is necessary and sufficient for binding early oligomeric intermediates during A~ 
polymerization into amyloid fibrils . The ability ofN1 to bind A~ oligomers is influenced 
by positively charged residues in two sites (23-31 and 95-1 05), and dependent on the 
length ofthe sequence between them. Importantly, we also show that N1 strongly 
suppresses A~ oligomer toxicity in cultured murine hippocampal neurons, in a C. 
elegans-based assay, and in vivo in a mouse model of A~-induced memory dysfunction. 
These data suggest that N1, or small peptides derived from it, could be potent inhibitors 
of A~ oligomer toxicity and represent an entirely new class of therapeutic agents for AD. 
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2.2 Introduction 
AD currently afflicts 35 million individuals worldwide, and this number is 
expected to increase dramatically in the coming decades as the population ages [149]. If 
effective therapies are not developed, the disease will continue to have a devastating 
medical and economic impact on society. AD is associated with progressive 
accumulation in the brain of the A~ peptide, a proteolytic fragment of the amyloid 
precursor protein (APP) [150]. Strong experimental evidence supports the notion that the 
disease process starts with the binding of soluble, oligomeric assemblies of A~ to 
proteins or lipids on the surface of nerve cells. These interactions are thought to be 
responsible for the synaptic dysfunction underlying the cognitive decline in AD [151]. 
So far, the identities of the molecules to which oligomers bind, as well as the nature of 
the downstream neurotoxic pathways, have remained largely enigmatic. 
Recently, the cellular prion protein (PrPc) has been identified as a high affinity 
receptor for A~ oligomers [132, 133, 152]. Several reports also suggest that PrPc could 
mediate the synaptotoxic effects of A~ oligomers [127, 129-131 , 139, 153, 154], although 
this evidence is still controversial [133 , 142, 155, 156]. The two putative binding sites 
for A~ oligomers identified in PrPc (residues 23-31 and 95-1 05) are both encompassed 
within the flexible, N-terminal tail ofthe molecule (residues 23-111) [132, 152]. This 
region is proteolytically released as part of the normal, cellular processing ofPrPc, to 
produce a soluble fragment called N1 [157-159]. Interestingly, an artificial, secreted 
form of PrPc was previously reported to suppress cognitive impairment in a mouse model 
44 
of AD [155]. These observations suggest that, even ifPrPc is not a mediator of A~ 
neurotoxicity, soluble forms ofPrP such as the N1 fragment could sequester oligomers in 
the extracellular space and block their synaptotoxic effects [160]. 
Here, we extend the characterization of the PrP-A~ interaction, and show that the 
N1 fragment is necessary and sufficient to bind A~ oligomers and to inhibit formation of 
A~ fibrils in polymerization assays. Moreover, we show that N1 potently blocks the 
toxic effects of A~ oligomers in neuronal cultures, as well as in two different animal 
models. Our data support the notions that small peptides derived from N1 could serve as 
novel therapeutic agents for AD, and that enhancing production of the naturally occurring 
N1 fragment might constitute a mechanistic strategy for treating AD. 
2.3 Methods 
a. Recombinant Proteins. 
Constructs were generated for murine PrP23-230, N1 (23-111), and C1 (112-230). 
3F4 tagged moPrP eDNA was amplified by PCR with a N-terminal6xHis tag and TEV 
cleavage sequence (MRGSHHHHHHGENL YFQG), a C-terminal Myc tag, and stop 
codon (EQKLISEEDL) using forward primer 1 (for PrP23-230 and N1): 5' -CACCATGCG 
CGGCAGCCAT CATCATCATC ATCATGGCGA AAACCTGTA TTTTCAGGGC 
AAAAAGCGGC CAAAGC, forward primer 2 (for C1): 5' -CACCATGCGC 
GGCAGCCATC ATCATCATCA TCATGGCGAA AACCTGTATT TTCAGGGCG 
TAGTGGGGGG CCTTGG, reverse primer 1 (forN1): 5'-TCACAGATCT 
TCTTCGCT AA TCAGTTTCTG TTCATGCTTC ATGTTGG, and reverse primer 2 (for 
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PrP23-230 and C1): 5'-TCACAGATCT TCTTCGCTAA TCAGTTTCTG TTCGGATCTT 
CTCCCGTCG. The PCR product was cloned into the pETl 01 TOPO vector (Invitrogen 
Grand Island, NY). The ligation product was transformed into TOP10 chemically 
competent E. coli (Invitrogen) and incubated overnight on LB plates with ampicillin. 
Colonies were picked and sequenced using a T7 forward primer. The sequenced DNA 
was then transformed into BL21 Star E. coli (Invitrogen) for protein expression. 
A single BL21 star colony was picked and grown overnight in 6 x 500mL of auto-
induction media (1% tryptone, 0.5% yeast extract, 25 mM Na2HP04, 25 mM KH2P04, 50 
mM NH4Cl, 5 mM Na2S04, 2 mM MgS04, 0.05% glucose, and 0.2% lactose) in 2L 
baffled flasks at 37C shaking at 300 rpm. The cell pellet was isolated by spinning 5,000 
rpm for 30 minutes at 4C in a Sorvall RC5+ superspeed centrifuge using a SLA-3000 
rotor (Sorvall- Thermo-Scientific, Hudson, New Hampshire). The cell pellet was 
resuspended in lysis buffer (lx PBS, 1% Triton X100, 1 mM EDTA, lx lysozyme, 
1mg/mL sodium deoxycholate) and freeze-thawed three times. DNA was sheared using 
10 x 20 second sonication pulses separated by a 30 second pause on ice. The soluble and 
insoluble fractions of the lysate were separated by spinning for 30 minutes at 12,500 rpm 
and 4°C in a SLA-34 rotor (Sorvall- Thermo-Scientific,Hudson, New Hampshire). 
For Nl , 5 mL ofHis60 Nickel resin (Clontech Laboratories, Inc. , Mountain View, 
CA) was washed at 1 mL/min with 10 column volumes of equilibration buffer (50 mM 
sodium phosphate, 300 mM sodium chloride, 20 mM imidazole, pH 7.4). Clarified 
(soluble fraction) sample was loaded onto the column. Unbound proteins were washed 
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using 10 column volumes (CV) of equilibration buffer. Loosely bound proteins were 
washed using 10 CV of wash buffer (50 mM sodium phosphate, 300 mM sodium 
chloride, 40 mM imidazole, pH 7.4). N1 was eluted with 5 CV of elution buffer (50 mM 
sodium phosphate, 300 mM sodium chloride, 300 mM imidazole, pH 7.4). 
For PrP23-230 and C1 , the insoluble fraction was washed 3x using PBS with 1% 
Triton X1 00. The purified inclusion bodies were dissolved in Buffer A (8 M urea, 100 
mM sodium phosphate, 10 mM tris-HCl, 10 mM 2-mercaptoethanol; pH 8.0). Insoluble 
proteins were removed by spinning at 12,500 rpm and 4°C for 10 minutes in a SLA-34 
rotor. Ten mL of Chelating Sepharose Fast Flow (GE Healthcare, Piscataway, NJ) resin 
was washed with 10 CV of ddH20. Resin was charged with 0.1 CV of0.2M NiS04. The 
column was equilibrated with 1 0 CV of Buffer A. Dissolved inclusion bodies were 
hatched and loaded onto the resin. Unbound proteins were removed by washing with 10 
CV of Buffer A. The proteins were refolded using an overnight linear gradient from 
Buffer A to Buffer B (100 mM sodium phosphate, 10 mM tris-HCl; pH 8.0). Loosely 
bound proteins were washed using 1 0 CV of Buffer C (1 00 mM sodium phosphate, 10 
mM tris HCl, 40 mM imidazole; pH 8.0). Proteins were eluted using 5 CV of Buffer D 
(100 mM sodium phosphate, 10 mM tris HCl, 300 mM imidazole; pH 5.0). Proper 
folding was confirmed by circular dichroism (CD). 
b. Preparation of AfJ Oligomers. 
A~1-42peptide was purchased from the Keck Biotechnology Resource Laboratory, 
Yale University, New Haven, CT. The peptide was dissolved in 1,1 ,1,3,3,3-hexafluoro-
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2-propanol (HFIP, Sigma), dried, reconstituted in anhydrous DMSO to a concentration of 
100 mM, and then diluted in F12 media (Invitrogen) to a fmal concentration of 100 !!M. 
After a 16 hour incubation at 22°C, each preparation was centrifuged at 14,200 x g for 
15 min, and the supernatant was used for experiments. 
c. Size Exclusion Chromatography. 
Aliquots (0.5 mL) of 100 !!M AB oligomers were injected into a Superdex 75 
10/300 column (GE Healthcare) and eluted using PBS with 0.05% Tween at a flow rate 
of0.7 mL/min using an AKTA FPLC (GE Healthcare, Piscataway, NJ). Peptide elution 
was monitored at 220 nm. 
d. Immunoprecipitation Assay. 
The PrP-A~ binding assay was performed as described previously [161]. A~ 
oligomers and recombinant PrP molecules were incubated in binding buffer (50 mM tris 
at pH 7.5, 200 mM NaCl, 0.1% NP-40) at 4 oc for 4 h. Anti-myc antibody 4A6 was 
cross-linked onto Dynabeads containing anti-mouse IgG (Invitrogen), and the beads were 
then incubated with each sample at 4 oc for 2 h. Beads were washed twice with binding 
buffer and re-suspended in loading buffer for immunoblot analysis. 
e. Surface Plasmon Resonance (SPR) . 
Binding studies were performed using the ProteOn XPR36 Protein Interaction 
Array system (Bio-Rad), as previously described [133]. Anti-myc antibody 9E10 (Santa 
Cruz) or 4A6 antibodies (Millipore) in 10 mM sodium acetate buffer at pH 4.5 were 
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immobilized on the service of a GLC sensor chip (Bio-Rad) using primary amine 
coupling after activation with 10 mM EDC/NHS. The surface was capped with 1M 
ethanolamine. Using PBS with 0.05% Tween and lmM EDTA as the running buffer, 
equimolar amounts of the PrP constructs were captured on the surface by anti-myc 
antibody. Monomeric, oligomeric or fibrillar A~ 1-42 preparations were then injected over 
the sensor chip. Non-specific binding and buffer interactions were subtracted from each 
sensorgram, and the resulting curves were fitted using a Langmuir interaction model 
(ProteOn analysis software) to obtain binding constants. 
f Thioflavin-T (ThT) Assay. 
Various concentrations of recombinant N1 and monomeric A~ 1-42 were incubated 
in 10 J..LM ThT, 50 mM phosphate buffer, pH 7.2 at 37 °C for 16 h with shaking. 
Fluorescence was measured in a Synergy H1MF plate reader (Biotek, Winooski, VT) 
every 10 minutes (Excitation: 440nm, Emission: 490nm). 
g. Nl Peptides. 
N1 peptides with a C-terminal myc tag were synthesized by American Peptide 
Company (Sunnyvale, CA, USA). Sequences were as follows: P1- KKRPK PGGWH 
NQWNK PSKPK TNLKH VEQKL ISEEDL; P2 - KKRPK PGGWN TGGSR YPGHN 
QWNKP SKPKT NLKHV EQKLI SEEDL; P3 - KKRPK PGGWN TGGSR YPGQG 
SPGGN RYPHN QWNKP SKPKT NLKHV EQKLI SEEDL; P4- KKRPK PGGWE 
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QKLIS EEDL; and P5 - HNQWN KPSKP KTNLK HVEQK LISEE DL. Peptide purity 
was greater than 90%, as assessed by HPLC and mass spectrometry (not shown). 
h. Primary Hippocampal Culture and Analysis of Synaptic Proteins. 
(Experiments performed by Tiziana Borsello and Alessandra Sclip) 
Primary neuronal cultures were derived from the hippocampus of two day 
postnatal mice and cultured as previously described [133]. Briefly, neurons were plated 
on 35 mm dishes (600,000 cells/dish) pre-coated with 25 mg/ml poly-D-lysine (P6407, 
Sigma) in B27/neurobasal-A medium supplemented with 0.5 mM glutamine, 100 U/ml 
penicillin, and 100 j.lg/ml streptomycin (all from Gibco-Invitrogen). Experiments were 
performed 12 days after plating. 
Neurons were exposed for 3 h to A~ oligomers (1 !lM) that had been pre-
incubated for 1 hat 4°C with N1 (1 !lM) or vehicle. Subcellular fractionation was 
performed as previously reported with minor modifications [162]. Briefly, neurons were 
homogenized using a Potter-Elvehjem in 0.32 Mice-cold sucrose buffer (pH 7.4) 
containing the following: 1 mM HEPES, 1 mM MgCh, 1 mM EDTA, 1 mM NaHC03, 
0.1 mM phenylmethylsulfonyl fluoride (PMSF), in the presence of protease (Complete; 
Roche) and phosphatase (Sigma) inhibitor cocktails. Samples were centrifuged at 3,000 
x g for 15 min to obtain a crude membrane fraction. The pellet was re-suspended in a 
buffer containing 75 mM KCl, 0.5% Triton X-100 and centrifuged at 100,000 x g for 1 h. 
The fmal pellet, referred to as the Triton insoluble fraction (TIF), was re-homogenized in 
20 mM HEPES supplemented with protease and phosphatase inhibitors, and stored at -80 
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oc or directly used in further experiments. The protein concentration in each solution 
was quantified using Bradford Assay (Bio-Rad), and 5 11g ofTIF-extracted proteins were 
then analysed by immunoblot [162]. Primary antibodies used were: anti-GluN2A and 
anti-GluN2B (each 1:2000, Gibco-Invitrogen), anti-GluAl and anti-GluA2 (each 1:1000, 
Millipore), anti PSD-95 (1 :2000, Cayman Chemical) and anti-tubulin (1 :5000, Santa 
Cruz). Immunoblots were quantified by densitometry using Quantity One software 
(Biorad). All experiments were repeated on six independent culture preparations (n=6). 
i. C. elegans Assay. 
(Experiments performed by Luisa Diomede) 
N2 worms were obtained from the Caenorhabditis Genetic Center (CGC, 
University of Minnesota, USA) and propagated on solid Nematode Growth Medium 
(NGM) seeded with E. coli (OP50, CGC, University of Minnesota, USA). Nematodes at 
L3-L4larval stage, were collected by washing plates with M9 buffer, transferred to tubes, 
centrifuged, and washed twice with 5 mM PBS, pH 7.4 to eliminate bacteria. Synthetic 
A~ 142 oligomers (0.1 ~-tM) were incubated with Nl (0.3 ~-tM in 5 mM PBS, pH 7.4) or 
anti-A~ antibody 4G8 (Covance, 1:500, vol:vol in 5 mM PBS, pH 7.4) at 25 °C for 30 
min, and administered to C. elegans (100 worms/100 ~-tl) [163 , 164]. After 2 h of orbital 
shaking, worms were transferred onto new NMG plates seeded with E. coli. The 
pharyngeal pumping rate was scored after 2 h of recovery by counting the number of 
times the terminal bulb ofthe pharynx contracted over a 1-minute interval. 
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j. Mouse Studies. 
(Experiments performed by Claudia Balducci and Pietro La Vitola) 
Mice were anesthetized with Forane (Abbott) and mounted on a stereotaxic 
apparatus (model900, David Kopf, CA). A 7 mm-long guide cannula was implanted into 
the cerebral lateral ventricle (L ± 1.0 and DV -3.0 from dura with incisor bar at 0°) and 
secured to the skull with two stainless steel screws and dental cement. Mice were 
allowed 10-15 days to recover from surgery before each experiment. For treatments, AP 
oligomers (1 )lM), prepared as previously described [133], and N1 (1 and 5 )lM) were co-
incubated on ice for 15 min before ICV microinfusion. The Novel Object Recognition 
(NOR) test was then performed following a previously published protocol [133]. 
Memory was expressed as a discrimination index [i.e. (seconds on novel object- seconds 
on familiar object) I (total seconds on both objects)]. Animals with no memory 
impairment spent a longer time investigating the novel object, which resulted in a higher 
discrimination index. 
2.4 Results 
a. Characterization of AfJ Oligomers. 
In order to study the interaction of PrP molecules and AP oligomers in vitro, we 
used synthetic APt-42 peptide that was denatured and oligomerized following a standard 
protocol to generate AP-derived diffusible ligands (ADDLs), hereafter referred to asAP 
oligomers. These preparations were first characterized by size-exclusion chromatography 
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(SEC) (Figure 9A). Monomeric A~ (blue line) migrates as a single peak, whereas A~ 
oligomers (red line) eluted earlier, the column void volume, with a second peak 
corresponding to the remaining monomers. These data are similar to results shown in 
previous studies [130, 164]. In order to extend the characterization of A~ oligomers, we 
also tested their reactivity with an oligomer-specific antibody (All) by a non-denaturing 
slot blot assay (Figure 9B). In this experiment, A~ monomers, oligomers and fibrils are 
immobilized on a nitrocellulose membrane and probed with different antibodies. As 
expected, we found that an oligomer-specific antibody (All) recognized A~ oligomers, 
but not monomers or fibrils. In contrast, an anti-A~ antibody (6E10) recognized all three 
samples. 
PrP23-230, Cl , and Nl were purified as described in the methods sections. PrP23-230 
eluted as a 25 kDa band, Cl a 15 kDa band, and Nl a 12 kDa band. The proteins were 
assayed for purity using SDS-P AGE with Coomassie blue staining. All proteins appeared 
to be greater than 90% pure (Figure 1 0). Proper protein folding was confirmed using CD. 
The far-UV spectra ofNl showed random coil structure, whereas Cl and PrP23-230 
showed alpha-helical structure (Figure 11 ). 
b. Nl Binds to Synthetic AfJ Oligomers with Nanomolar Affinity. 
In order to test whether PrPc or the Nl fragment interact with A~ oligomers, we 
incubated full-length, recombinant PrPc (residues 23-230, hereafter referred to as PrP23 -
230) and N 1 (residues 23-111 ), with synthetic A~ oligomers, prepared and characterized 
following previously defmed conditions [133, 152]. PrP23-230 and Nl used in these 
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studies were each tagged with a myc epitope at the C-terminus of the peptide. As a 
negative control, we used another myc-tagged PrP fragment (residues 112-230, called 
C 1 ), which is equivalent to the C-terminal half of PrPc that remains attached to the cell 
membrane after cleavage ofthe N1 fragment [157-159]. An anti-myc antibody (4A6) 
was used to immunoprecipitate the different PrP molecules. The presence of A~ in each 
immunoprecipitation reaction was then tested by immunoblot analysis. We found that 
A~ oligomers co-precipitated with both PrP23-230 and N1, but not C1 (Figure 12). These 
results indicate that PrP23-230 and N1, but not C1, are able to bind A~ oligomers. 
To further validate these results, we employed surface plasmon resonance (SPR), 
a technique that allows estimation of kinetic and binding constants for protein-protein 
interactions [132, 133]. Myc-tagged PrP23-230, Nl, or Cl were captured on the surface of 
separate SPR chips that have previously been coated with anti-myc antibody 4A6. 
Different concentrations of synthetic A~ oligomers (Figure 13), monomers or fibrils (not 
shown) were then assayed for binding. We detected dose-dependent binding of A~ 
oligomers, but not monomers or fibrils, to PrP23-230 and Nl. These two PrP molecules 
showed almost identical affinities for A~ oligomers with a Kct of 30 x 1 o-9 M for PrP23-230 
and 17 x 10-9 M for Nl. In contrast, no binding was observed when C1 (Figure 13), or 
anti-myc antibody alone (not shown) were immobilized. The binding constants Ckon, koff 
and Ko) for the interaction ofPrP23-230 or N1 with A~ oligomers were comparable to the 
values we described in a previous report for brain-derived PrPc [133]. Of note, the 
concentration of A~ oligomers in this assay was based on the concentration of monomers 
54 
used as starting material. However, since each A~ oligomer particle contains multiple 
subunits, the actual concentration of oligomers is lower than estimated. Therefore, the 
affinity ofPrPc or Nl to A~ oligomers, as calculated by SPR, is likely to be in the sub-
nanomolar range; e.g., if each oligomeric particle includes 50 A~ monomers, the affinity 
calculated by SPR is 50 times higher. 
Collectively, these results demonstrate that theN-terminal region ofPrPc, 
corresponding to the Nl fragment, is necessary and sufficient for binding to synthetic A~ 
oligomers. Therefore, all subsequent experiments were conducted with Nl 
c. Nl Binds to a Transient Population of A/3 Oligomers and Inhibits Formation of 
Amyloid Fibrils. 
In order to further characterize the PrP-A~ interaction, we tested binding ofNl 
(Figure 14A) or Cl (not shown) to different A~ assemblies formed during polymerization 
into amyloid fibrils. Freshly re-dissolved, synthetic A~ peptide was incubated in a 
polymerization buffer at 3 7 oc for 8 h. Aliquots of the polymerization reaction were 
collected every 2 h and immediately flowed over SPR sensor chips on which myc-tagged 
PrP molecules had already been captured with an anti-myc antibody. These analyses 
revealed that Nl, but not Cl, binds to a population of A~ assemblies that first appear after 
2 h of incubation, with the highest levels ofbinding detected at 4 h (Figure 14A, 2nd and 
3rd panels from the left). Our data are consistent with the kinetics of formation of A~ 
oligomers previously reported [164]. No binding was detected at 8 h, or at later time 
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points (not shown). These results indicate that the AP species recognized by Nl are 
generated transiently, early during the polymerization reaction. 
Based on this evidence, we predicted that N1 could act as a solub~e inhibitor of 
AP polymerization, blocking the formation of amyloid fibrils. To test this hypothesis, we 
utilized a ThT-based assay. ThT fluorescence shifts to red when the dye binds toP-sheet-
rich protein assemblies [165]. This effect is stronger for mature amyloid fibrils than for 
oligomeric assemblies of AP [166]. Therefore, the formation of Ap fibrils can 
conveniently be followed in real-time by detecting ThT fluorescence. We incubated 
freshly re-dissolved Ap in a buffer containing 10 J..LM ThT, in the presence of different 
concentrations ofNl or Cl, and then monitored the fluorescence ofThT for 16 hat 37 oc 
(Figure 14B). In the absence ofNl, AP polymerization proceeded with a lag phase (0-2 
h) followed by rapid oligomerization and fibril growth (2-6 h), reaching a plateau after 6-
8 h. In the presence ofNl, but not C1, AP polymerization was delayed in a dose-
dependent manner, with a significantly extended lag phase (6-16 h; Figure 2-6B). At the 
highest dose ofN1 tested (2.5 J..LM; corresponding to a 1:8 molar ratio ofN1 :Ap), 
polymerization of AP was almost completely inhibited. These data demonstrate that N1 
binds to and stabilizes an intermediate AP form that appears along the polymerization 
pathway, blocking further maturation of AP into amyloid fibrils. 
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d. Positively Charged Residues in Two N-terminal Regions of PrPc Dictate Amount or 
Size of A/3 Oligomers Captured, Not Affinity of Binding. 
Recent reports have identified two major A~-binding sites in theN-terminal half 
ofPrPc (residues 23-31 and 95-105) [132, 152]. Both of these regions contain multiple 
basic residues, a feature that may directly determine their ability to interact with A~ 
oligomers. In order to test the role of these positively charged residues in the PrP-A~ 
interaction, we engineered N1 molecules carrying multiple substitutions that abolished 
the positive charges in the two A~-binding regions. Residues 23-27 (KKRPK) were 
mutated to GAAPA and residues 95-110 (HNQWNKPSKPKTNMKH) were mutated to 
HNQWNAPSAPATNMAH (Figure 15A). The interaction ofthis mutant form ofNl 
(referred to as "neutral" N1, or nN1) with A~ oligomers was then tested by SPR. Similar 
amounts ofNl and nNl were captured on the surface ofthe SPR chip, as demonstrated 
by binding of an anti-PrP antibody (SAF32) to the chip surface (Figure 15B). We 
observed significantly reduced binding of A~ oligomers to nNl as compared to the wild-
type Nl control (Figure 15B). Surprisingly, Nl and nNl showed similar dissociation 
constants and on/off rates for binding to A~ oligomers (Ko = 19 x 10·9 M for N1; and K0 
= 20 x 10·9 M for nNl). These results suggest that the positively charged amino acids in 
the two Af3 binding sites do not dictate the kinetics of association between Nl and Af3 
oligomers or the stability of the complex; however, these basic residues on Nl do appear 
to influence the capacity ofthe molecule to capture Af3 possibly as a function of 
oligomeric size. 
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e. Ability ofNJ to Bind AfJ Oligomers Influenced by Residues 32-94. 
To further characterize the interaction ofN1 with A~ oligomers, we synthesized a 
series ofN1-derived peptides carrying different deletions between the two predicted 
binding sites (23-31 and 95-105), referred to as P1 (1'151-94), P2 (1'141-94), and P3 (1'131-
94). Two additional peptides corresponding to the individual binding sites, called P4 and 
P5 (residues 23-31 and 95-105, respectively), were used as controls (Figure 16A). 
In order to analyze the relative ability of the different N1 peptides to bind A~ 
oligomers, we immunocaptured myc-tagged, recombinant N1 and synthetic peptides in 
parallel lanes of a SPR chip. A~ oligomers were then flowed across the different lanes, 
and the interactions measured simultaneously (Figure 16B). We found that deleting the 
octarepeat region (P1, 1'151-94) decreased binding to A~ oligomers by approximately 
39%. Binding was further diminished by deleting 10 additional residues (P2, 41-94; 72% 
reduction), and almost completely abolished by extending the deletion to residue 32 (P3, 
32-94, 92% decrease). Similarly, binding was barely detectable for peptides 
corresponding to each individual binding site (P4 and P5, 96% and 99%, respectively). 
These data demonstrate that binding ofN1 to A~ oligomers also depends on critical 
residues between the two binding sites (23-31 and 95-1 05). 
Two explanations may account for the influence of residues 32-94 on A~ 
oligomers binding to N1. The residues between the binding sites could act as a spacer 
between the two regions, providing an ideal alignment of the interacting residues on N1 
for A~ oligomers. A second possibility is that residues 32-94 may contribute to binding. 
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To examine the role of size between the binding sites, we captured a 50:50 mixture of 
peptides P4 and P5 using a previously immobilized anti-myc antibody on the surface of 
an SPR chip (Figure 17). Assuming an idealized distribution ofthe peptide, 50% ofthe 
antibodies should contain one P4 peptide and one P5 peptide. After injection of AP 
oligomers, we observed a maximal binding of290 RUs to N1, 225 RUs to Pl , and 145 
RUs for the P4:P5 mixture. AP oligomers showed only slight binding with P4 and P5. 
Adjusting for the 50% distribution of the P4:P5 mixture, the binding of Ap oligomers to 
the P4:P5 lane is similar to the N1 lane. These results suggest that the distance between 
residues 23-31 and 95-105 is crucial for oligomer binding. 
f Nl Blocks AfJ Oligomer-mediated Loss of Post-synaptic Markers in Hippocampal 
Neurons. 
In order to test the relevance of the N1-AP interaction at a biological level, we 
sought to determine whether N1 could rescue the toxic effects of AP oligomers in 
primary neuronal cultures, as measured by detecting the levels of five postsynaptic 
marker proteins. Postnatal mouse hippocampal neurons were kept in culture for 12 days 
and then incubated for 3 h with AP oligomers. The amounts of several glutamate 
receptors subunits and other post-synaptic markers were analyzed by immunoblots of the 
Triton-insoluble fractions. A representative immunoblot is shown in Figure 2-1 OA. A 3 
h treatment with AP oligomers (1 11M) induced significantly decreased levels of GluN2A 
and GluN2B, two subunits of the NMDA receptor (Figure 2-lOB i-ii), and GluAl and 
GluA2, subunits ofthe AMPA receptor (Figure 18B, iii-iv), compared to controls 
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(p<0.01). Specifically, A~ oligomers caused a 60% reduction of GluN2A and GluN2B, 
and 70-73% decrease in GluA1 and GluA2. Moreover, a 70% reduction of the 
postsynaptic density protein 95 (PSD95, Figure 2-10B, v) was observed in the cells 
exposed to A~ oligomers. While the levels of these proteins were not significantly 
affected by treatment with 1 J..LM N1 alone, pre-incubation of A~ oligomers with N1 (in a 
1:1 molar ratio) for 1 h significantly rescued the levels of all these synaptic markers. 
Compared to cells treated with A~ oligomers, the levels ofGluN2A, GluN2B, GluA1, 
GluA2, and PSD95 in the A~+N1 exposed cells were significantly increased by 65, 73, 
66, 104, and 55% respectively (p<0.01). The level of a control protein (tubulin) was not 
affected by either A~ oligomers or N1 (Figure 2-1 OB, vi). These results indicate that the 
presence ofN1 antagonizes the A~ oligomer-mediated loss of synaptic markers. 
g. Nl Blocks Disruptive Effects of AfJ Oligomers in Animal Models. 
To validate these results in vivo, we turned to two different animal models of A~ 
toxicity. The first utilizes the nematode, C. elegans. The pharyngeal pumping rate of C. 
elegans can be rapidly reduced by sub-lethal doses of chemical stressors. A previous 
report showed that both rhythmic contraction and relaxation of the pharyngeal muscle in 
C. elegans are significantly impaired (approximately 50%) by feeding the nematodes 
with synthetic A~ oligomers [164]. Although it remains uncertain whether the 
biochemical mechanisms underlying A~ toxicity in worms and humans are identical, this 
model has been previously utilized as a surrogate assay for A~ toxicity. Here, we 
employed this assay to test the anti-A~ effect ofN1. Consistent with previous 
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observations, the pumping rate of the worms was significantly impaired when they were 
fed 0.1 f..LM A~ oligomers (Figure 19A). We tested Nl alone and found a slight, but 
significant inhibitory effect of the peptide on pumping rate when concentrations of 0.5 
f..LM or higher were used, i.e. 5% and 10% inhibition at 0.5 and 1 f..LM respectively (data 
not shown). However, no effect was observed when N1 was administered at 
concentrations lower than 0.5 f..LM. Pre-incubation of 0.1 f..LM A~ oligomers with 0.3 f..LM 
N1 robustly antagonized the oligomer-dependent effect on pumping rate (Figure 19A), 
p<O.Ol. The inhibitory effect ofN1 was comparable to that of an anti-A~ antibody (4G8) 
[164] (not shown). These results demonstrate that N1 counteracts the toxic effects of A~ 
oligomers in vivo using C. elegans as a model system. 
To further substantiate these observations, we evaluated the protective effect ofN1 
on memory dysfunction caused by intracerebroventricular (ICV) injection of synthetic A~ 
oligomers in mice, using a novel-object recognition (NOR) task. This assay was recently 
applied to demonstrate that synthetic A~ oligomers induce memory impairment in mice 
in a PrPc-independent fashion [133]. Here, we hypothesized that, regardless of whether 
PrPc mediates the neurotoxicity of A~ oligomers, the Nl fragment could sequester 
oligomers in the extracellular space and prevent their toxic effects. To test this 
hypothesis, synthetic A~ oligomers (lf..LM) were incubated with various amounts ofNl 
(0, 1 or 5 f..LM) for 15 min before microinfusion into the lateral ventricle of C57BL/6 
mice. Animals were initially trained in an arena containing two objects that they could 
explore freely (familiarization phase), and 24 hours later, exposed to one familiar and one 
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new object (test phase). As expected, mice treated with A~ oligomers were unable to 
distinguish the new object; e.g. there was no significant difference in the percentage of 
time spent investigating new and old objects (Figure 19B) as compared to vehicle-
injected controls. However, pre-incubation of A~ oligomers with Nl rescued the 
behavioral impairment in a dose-dependent fashion (Figure 19B). These results 
demonstrate that Nl blocks the A~ oligomer-induced memory impairment in vivo. 
2.5 Discussion 
Despite uncertainty regarding the role of cell surface PrPc in mediating the toxic 
effects of A~ oligomers, the ability of these two molecules to interact with high affinity is 
widely accepted [167]. In this paper, we present a detailed characterization ofthe 
binding interaction between A~ oligomers and the major, soluble, physiologically 
generated, N-terminal fragment ofPrPc (Nl). We show that Nl fully retains the ability 
to bind A~ oligomers, while the entire C-terminal half ofPrPc is dispensable. Nl binds 
selectively to transient A~ intermediates formed during the polymerization and amyloid 
fibril formation, thereby inhibiting the process. We also report that the binding capacity, 
but not the affinity, ofNl for A~ oligomers is influenced by at least two factors: 1) 
positively charged residues in the two A~-binding sites (23-31 and 95-1 05), and 2) the 
distance between the two sites. Finally, we demonstrate that N1 is a potent inhibitor of 
A~ toxicity, based on its ability to prevent the detrimental effects of A~ oligomers in 
cultured hippocampal neurons, C. elegans, and mice. Collectively, these data argue that, 
62 
whether or not the neurotoxicity of A~ oligomers is eliCited in a PrPc -dependent fashion, 
N1-based compounds may represent novel tools for preventing their neurotoxic effects. 
a. How does PrP interact with AfJ oligomers? 
Previous studies have identified two distinct regions in PrPc involved in the 
binding of A~ oligomers. The first site (residues 95-1 05) was mapped by employing a 
combination of deletion mutants and antibody treatments [152], while the second domain 
(residues 23-27) was identified using SPR and electron paramagnetic resonance (EPR) 
spectroscopy [132]. Synthetic peptides corresponding to each individual binding site 
failed to inhibit aggregation A~ oligomers [160]. Our SPR data confirms that peptides 
containing the two individual binding sites alone or combined do not interact with A~ 
oligomers, suggesting that additional regions in theN-terminus ofPrPc may contribute to 
the binding. Further, our data suggest that efficient binding requires separation of the two 
sites by additional amino acids. Future studies, will address whether this phenomenon 
depends only on the distance separating the two sites, or whether there is a sequence-
specific contribution of particular residues in the linker region, or both of these factors. 
Results from our SPR experiments showed, surprisingly, that basic residues 
within the two A~-binding sites did not influence the affinity ofN1 for A~ oligomers. 
However, a lower mass of A~ oligomers interacted with N1 that lacked positively 
charged residues in the binding domains. This effect seems plausible if smaller A~ 
oligomers were captured by the neutralized PrP sites. Therefore, the presence of 
positively charged residues in the two A~ binding sites could determine the size of the 
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oligomers that interact with PrPc. Our data also suggest that binding between Nl and A~ 
oligomers does not depend on simple electrostatic interactions between the negatively 
charged residues on A~ and positively charged amino acids on PrPc. Rather, a 
conformational rearrangement of the flexible, N-terminal domain ofPrPc could govern 
the interaction with A~ oligomers. This observation is further supported by our 
observation that the binding ability of the PrPc N-terminus is influenced by the length of 
the region separating the two binding regions. Further studies are needed to validate this 
hypothesized mechanism. 
Our observation that Nl binds to A~ species generated early during the 
polymerization process is consistent with evidence that neither monomeric nor fibrillar 
forms of A~ have significant affinity for PrPc, and that binding is specific for A~ 
oligomers. Importantly, Nl is capable of markedly suppressing the A~ polymerization 
process itself, as measured by ThT binding, suggesting that interaction with Nl blocks or 
slows further growth of oligomers into elongating fibrils. Similar effects on A~ 
polymerization have also been reported recently by Nieznanski et al. using longer 
portions ofthe PrP molecule [160]. 
b. Nl neutralizes toxic assemblies of AfJ. 
Previous studies reported that Nl exerts a neuroprotective effect in neuronal cells, 
by reducing p53-mediated cell death [98]. Recently, Nl was also shown to protect 
neurons against the cytotoxic effects of A~ monomers and oligomers through activation 
of intracellular cell survival mechanisms involving the Akt/p53 pathway [97]. Another 
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recent study using cell viability assays provided experimental support for the notion that 
Nl interacts directly with A~ oligomers, blocking their neurotoxicity in transformed cell 
lines [160]. Here, we show for the first time that Nl counteracts A~ effects in primary 
neurons, and suppresses A~ toxicity in two different animal models, C. elegans and mice. 
These effects were seen when Nl was mixed with pre-formed A~ oligomers, even at low 
stoichiometric ratios, suggesting that Nl blocks the interaction of a specific oligomeric 
form of A~ with cellular receptors responsible for toxicity. Whether such receptors 
include PrPc itself remains to be determined. 
In principle, attempts to develop A~-directed agents would be facilitated by 
knowing the structure of the toxic A~ species at high-resolution. Unfortunately, research 
has been hampered by the fact that A~ assemblies are often structurally heterogeneous 
and metastable. In this study, we observe that Nl stabilizes a particular subset of A~ 
assemblies and inhibits the neurotoxic effects of A~ preparations in vitro and in vivo. 
Such a rescue effect provides evidence that A~ species recognized by Nl are neurotoxic. 
Therefore, as also suggested by a recent study [139], Nl-based compounds may allow the 
isolation oftoxic A~ species from biological samples (e.g. cerebrospinal fluid) or 
quantitation of the amount of toxic species in clinical samples. Moreover, the 
biophysical characterization of the complex formed by synthetic A~ oligomers and Nl 
could provide important insights regarding the oligomerization pathway and the structure 
of toxic A~ oligomers, laying the groundwork for the rational design of anti-AD 
therapeutics. 
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c. N 1-based therapies for treatment of neurodegenerative diseases. 
Soluble A~ oligomers represent a primary pharmacological target for reducing 
synaptic dysfunction and cognitive decline in AD [168]. For example, anti-A~ antibodies 
have been extensively tested in animal models and human patients. Although such 
therapeutics have not proven effective in clinical trials, this may be because they have not 
been administered early enough in the disease process [169]. Our data indicate that N1 
interacts with A~ oligomers with an affinity comparable to anti-A~ antibodies and blocks 
toxicity in a variety of experimental settings including cells, worms and mice. 
Therefore, development ofN1-based compounds, e.g. short N1-derived peptides may 
represent a novel pharmacological approach for treatment of AD. 
N1 is a naturally occurring, soluble fragment that is generated by endogenous 
proteolytic processing of membrane-bound PrPc at the a-site, residues 1111112 [158]. 
Up to 50% of the PrPc in brain cells is cleaved at this site. There is uncertainty about the 
identity and cellular location of the relevant proteases, although cell-surface ADAM 
proteases represent one set of candidates [157]. Importantly, a cleavage ofPrPc can be 
stimulated pharmacologically, e.g. by activators of protein kinase C [170]. It is possible 
that such agents could have therapeutic effects in AD by increasing production of the 
neuroprotective N1 fragment. 
A recent study provided evidence that PrPc could bind not only A~ oligomers, but 
also other ~-sheet-rich protein assemblies [134]. This unexpected property ofPrPc seems 
to rely on the same N-terminal domains that are involved in binding to A~ oligomers, i.e. 
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residues 23-31 and 95-105. Therefore, it is possible that N1-derived compounds will 
possess the ability to block the neurotoxic effects of other amyloidogenic protein 
oligomers linked to different neurodegenerative diseases. 
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Figure 9. Biochemical characterization of AP preparations. 
(A) Size-exclusion chromatography of A~ preparations eluted in PBS. In contrast to 
monomeric A~, which produced a single peak (blue line), oligomer preparations 
produced two peaks (red line), one corresponding to 4 kDa the residual monomer, and a 
second, higher molecular size peak eluting near the void volume that corresponds to 
oligomers. An elution trace with buffer (black line) is shown for comparison. (B) Slot 
blot analysis of A~ monomers, oligomers and fibrils. Oligomer-directed antibody All 
recognizes A~ oligomers, but not monomers or fibrils. In contrast, anti-A~ antibody 
6E 1 0 recognizes all three species. 
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Figure 10. Purification of PrP Constructs. 
Protein samples collected during the purification ofPrP23-230, Nl, and Cl were separated 
by SDS-PAGE under reducing conditions and analyzed by Coomassie blue staining. The 
elution step produced a 25k:Da band for PrP23-230, 12k:Da band for Nl, and a 15 k:Da 
band for Cl. All purified samples were greater than 90% pure. (Lanes: MWM-
Molecular weight marker, Lysate- starting clarified sample before loading on IMAC 
column, FT- unbound proteins after the IMAC column, Wash- nonspecific proteins 
after 40mM imidazole wash, and Elution- elution of protein with 300mM imidazole) 
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Figure 11. Secondary structural analyses of PrP constructs. 
CD spectra ofPrP23-230, Nl, and Cl in lOmM Phosphate Buffer pH 7.2. PrP23-230 and Cl 
(5 uM of each protein sample) spectra showed high alpha helical content whereas Nl 
showed random coil folding. 
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Figure 12. Nl binds to synthetic AP oligomers. 
Recombinant, myc-tagged PrP23-230, N1 , and C1 (1 !-LM) were incubated with A~ 
oligomers (1 !-LM) and immunoprecipitated using blank beads (lanes 1, 3, 5) or beads 
coated with anti-myc antibody 4A6 (lanes 2, 4, 6). Samples were analyzed by Western 
blot using anti-myc antibody 4A6 (upper panel) or anti-A~ antibody 6E10 (lower panel). 
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Figure 13. PrP23-230 and Nl interact with AP oligomers with similar binding 
constants. 
Different concentrations of synthetic A~ oligomers were injected for 3 min over sensor 
surfaces on which 1,200 RU ofPrP23-230, N1 or C1 had been previously captured by anti-
myc antibody 4A6, followed by a wash with buffer alone. Sensorgrams show A~ binding 
in resonance units (RU). A~ oligomers bind to PrPc or N1 in a dose-dependent manner, 
but do not bind to C 1. The data were fitted using the Langmuir equation, modeling a 
simple bimolecular interaction (black line, for PrP23-230 : kon = 1.69 x 103 M-1s-1; koff= 
5.21 x 10-5 s - l; Ko = 30 x 10-9 M; for N1: kon = 4.29 x 103 M-1s-1; koff = 7.44 x 10-5 s - 1; 
K0 = 17 x 10-9 M). 
76 
PrP23-23o N1 C1 
100 100 100 
BO 80 BO ... 4pM A~ Ollgomers 
. v 2pM A Ollgomers 
.. 
: ri~s~~ Ag~~~~:i.':rs 60 60 60 ~ 
a:: 
40 40 40 
20 20 20 
200 400 600 BOO 200 400 600 BOO 200 400 600 800 
Time (s) Time (s) Time (s) 
77 
Figure 14. Nl binds selectively to AP species generated early during the 
polymerization process. 
(A) Solutions containing different concentrations of freshly re-dissolved A~ peptide 
were incubated at 3 7 °C, and every 2 hours during the polymerization process samples 
were collected and injected for 3 min over sensor surfaces on which recombinant, my-
tagged Nl have previously been captured by antibody 4A6. Chips were then washed 
with buffer alone. Maximal amounts of PrP-binding A~ species were present after 4 h of 
polymerization. (B) A 20 J.tM aliquot of freshly re-dissolved A~ peptide was incubated 
with 10 f!M ThT at 37 °C for 20 h, in presence or absence ofNl or Cl. Polymerization 
was monitored by detecting ThT fluorescence (Excitation: 440nrn, Emission: 490nrn). 
Nl inhibited A~ polymerization in a dose-dependent fashion, whereas Cl had no effect. 
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Figure 15. Neutralization of charged residues in Nl reduces binding to Afl 
oligomers without affecting binding constants. 
(A) Each of the four positively charged amino acids (indicated in red) in the two A~ 
binding regions were mutated to glycine or alanine, and the corresponding recombinant 
Nl mutant molecule (nNl) was expressed and purified. (B) A~ oligomers, or anti-PrP 
antibody SAF32, were injected for 3 min over sensor surfaces on which 800 RU ofmyc-
tagged, recombinant Nl or nNl had been previously captured by antibody 4A6, followed 
by buffer wash. The data were fitted using the Langmuir equation. Mutations in nNl 
reduced the interaction with A~ oligomers (calculated as maximum observed binding) by 
56.9%. However, similar kinetic constants were measured for Nl and nNl (for Nl: kon = 
4.03 x 103 M-ls- 1, koff= 7.68 x 10-5 s-1, Kn = 19 x 10-9 M, Rmax = 490.26 RU; for nNl: kon 
= 2.52 x 103 M-ls-1, koff= 5.23 X 10-5 s-\ Kn = 20 X 10-9 M, Rmax = 210.92 RU). 
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Figure 16. Binding of Nl to Afl oligomers is strongly influenced by residues 32-94. 
(A) Schematic ofNl peptides. Peptides were synthesized with a series of deletions 
between the two predicted binding sites (23-31 and 95-105): PI (~51-94), P2 (~41-94), 
and P3 (~31-95). Two additional peptides corresponding to each individual binding site, 
called P4 and P5 (residues 23-31 and 95-111 , respectively) were used as controls. (B) A~ 
oligomers (1 JlM) were injected for 4 min over sensor surfaces on which 320 RU ofmyc-
tagged Nl , 150 RU ofPl , 115 RU ofP2, 85 RU ofP3, 30 RU ofP4, and 60 RU ofP5 
had been previously captured by anti-myc antibody 4A6, followed by buffer wash. 
Deletions between the two binding sites (23-31 and 95-1 05) progressively reduced 
binding to A~ oligomers: 39% for P1 , 72% for P2, for 92% for P3. P4 and P5 did not 
bind a significant amount of A~ oligomers. Curves for binding to Nl , P1 , and P2 were 
fitted using the Langmuir equation, modeling a simple bimolecular interaction (white 
line, for N1: kon = 1.60 x 103 M"1s-1; koff = 6.54 x 10-5 s - 1; Kn = 40 x 10-9 M; for PI: kon = 
8.71 x 103 M"1s-1; koff = 1.11 x 104 s-1; Kn = 12 x 10"9 M; for P2: kon = 5.21 x 103 M"1s-1; 
koff= 1.37 x 104 s·1; Kn = 26 x 10"9 M). Signals for P3, P4, and P5 were too low to be fit. 
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Figure 17. Binding ofNl to Ap oligomers is influenced by the distance between 
binding sites. 
A~ oligomers (2 f!M) were injected for 4 min over sensor surfaces on which myc-tagged 
Nl, Pl, P4, P5 and a 50:50 mixture ofP4:P5 had been previously captured by anti-myc 
antibody 4A6, followed by buffer wash. The 50:50 mixture ofP4:P5 showed increased 
binding compared to P4 or P5 alone. P4 and P5 did not bind a significant amount of A~ 
oligomers. 
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Figure 18. Nl antagonizes the loss of post-synaptic makers of AP oligomers in 
cultured neurons. 
Cultures of hippocampal neurons were treated for 3 h with vehicle (CTR), Nl alone (1 
f.!M), A~ oligomers alone (1 f.!M), or A~ oligomers pre-incubated with Nl. Post-synaptic 
marker proteins were then measured by Western blotting. (A) Shows representative 
Western blots, and (B) shows quantification of several, independent (n=6) experiments. 
A~ oligomers induced a loss of post-synaptic markers, which was significantly attenuated 
by pre-incubation with Nl (Values are means± SEM; two-way ANOVA, Bonferroni 
post hoc test, **p<O.Ol CTR vs A~ oligomers, ## p<O.Ol A~ oligomers vs A~ 
oligomers+Nl , $ p<0.05 Nl vs A~ oligomers + Nl , n=6). Tubulin levels (vi) were not 
affected by A~ oligomer treatment (Two way ANOVA, p>0.05, n=6). 
(This experiment was done by Tiziana Borsello & Ales sandra Sclip.) 
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Figure 19. Nl antagonizes the toxic effects of Afl oligomers in animal models. 
(A) Freshly dissolved A~1-42 (100 J..LM) was incubated at 25°C for 5 h, diluted to 10 J..LM 
in 5 mM PBS, pH 7.4, and incubated, or not, for a further 30 min with N1 (0.3 J..LM in 
PBS). Samples were then administered to worms. Control worms were fed vehicle or 
0.3 J..LM N1 alone. Pharyngeal pumping rate was scored after 2 h of recovery by counting 
the number of times the terminal bulb ofthe pharynx contracted over a 1-minute interval 
(pumps/min). Values are means± SEM (n=30). Two-way ANOVA showed that Nl 
significantly reduced the inhibitory effect of A~ on pumping rate (p<O.Ol); **p<O.OOl 
A~ versus vehicle (CTR); and 00p<0.001 A~ versus of A~+ N1 (Bonferroni's test). (B) 
The effect of A~ oligomers (1 J..LM) on memory was investigated in C57BL/6 male mice 
using a novel-object recognition task after intracerebroventricular injection (ICV) 
injections (7.5 ) .. tl), in presence or absence ofNl. Bars show the discrimination index 
(mean± SEM) for exploration of the familiar vs. the novel objects. Mice treated with A~ 
oligomers (n = 19) spent equal time investigating both objects, while vehicle-injected 
controls (CTR, n = 21) spent significantly more time investigating the novel object 
(*P<0.05; Student's t-test). The memory impairment effect was abrogated when A~ 
oligomers were incubated with Nl before injection (for 1 J..LM Nl, n = 8; for 5 J..LM N1, n = 
17). One-way ANOVA (F2,41 = 4.7; P = 0.015) and Tuk:ey's post-hoc test (#P < 0.05) 
revealed a significant recovery of memory in mice receiving Nl at 5 J..LM compared to A~ 
oligomer-treated mice. (The mouse behavioral studies were done by Claudia Balducci 
and Pietro La Vitolall; the C. Elegan assay was performed by Luisa Diomede) 
88 
A. 
300 
Q)-
10 ·= 250 ~ E 
m-c tiJ 200 
·- Q. o.E 
E = 100 ::I Q. 
** 
00 
- ~ - I 
c..-
50 
0 . 
CTR N1 AP + N1 
B. 
* 0.3 
# 
>< 0.2 Cl) , 
c 
c 
0 ; 0.1 ftl 
c 
·e 
"i: 
u 
tiJ 0.0 c 
CTR All All + All+ 
-0.1 Nl (111M) Nl {5 J!M) 
89 
Chapter 3. Small molecule ligand for cellular prion protein inhibits neurotoxicity of 
amyloid-beta oligomers 
(This chapter is written as a manuscript for publication. The complete list of contributors 
is as follows: Emiliano Biasini*, Nunzio Iraci*, Brian R. Fluharty*, Jennifer L. Helfer, 
Tania Massignan, Kelli E. Cox, Erin A. Bove-Fenderson, Isaac H Solomon, Natasha 
Khatri, Paul Everill, Matteo Stravalaci, Marco Gobbi, Alessandra Sclip, Tiziana 
Borsello, Stefano Sabatini, Violetta Cecchetti, Oscar J Ingham, Aaron B. Beeler, 
Maria Letizia Barreca and David A. Harris (*authors contributed equally). Nunzio 
Iraci wrote the molecular dynamics section and made Figure 19, Emiliano Biasini and I 
wrote the remaining sections). 
3.1 Summary 
Soluble oligomers of the amyloid-~ (A~) peptide, a cleavage product ofthe 
amyloid precursor protein, are primarily responsible for synaptic dysfunction in 
Alzheimer's disease (AD). The cellular prion protein (PrPc), a cell surface glycoprotein 
involved in transmissible spongiform encephalopathies, has been shown. to bind A~ 
oligomers and transduce downstream synaptotoxic signaling. Thus, PrPc may represent a 
novel therapeutic target for treatment of AD. Here, we describe the identification of a 
high-affinity ligand for PrPc that blocks the neurotoxic effects of A~ oligomers in cell 
cultures and brain slices. The compound exerts this activity by inducing an unexpected 
self-inhibitory change in PrPc, which blocks interaction with A~ oligomers. These 
results provide the first example of an entirely new class of potential AD therapeutics 
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directed against PrPc -mediated neurotoxic pathways, rather than formation or clearance 
of A~. 
3.2 Introduction 
AD is the most common cause of memory loss in the elderly population and the 
5th leading cause of death in this group, currently affecting almost 50 million individuals 
worldwide [2]. This number is expected to increase dramatically in the coming decades 
as the population ages, thus producing devastating medical and socio-economic 
consequences. Although some of the basic molecular mechanisms underlying AD have 
been identified, this has not resulted in effective treatments for this devastating disorder 
[168]. The disease is associated with accumulation in the brain ofthe 40-42 amino acid 
amyloid-~ (A~) peptide, a cleavage product of the amyloid precursor protein (APP) 
[150]. A~ spontaneously forms polymers ranging from small, soluble oligomers to large, 
insoluble amyloid fibrils. Compelling evidence suggests that soluble A~ oligomers, 
rather than fibrillar aggregates, are primarily responsible for the synaptic dysfunction, 
thought be the underlying cause of cognitive decline in AD [31]. A~ oligomers are 
believed to act by binding to cell surface receptors which transduce their detrimental 
effects on synapses. Unfortunately, the identity of such receptors is still uncertain. 
Determination of neuronal binding sites for A~ oligomers has important therapeutic 
implications, since these receptors represent potential targets for pharmacological 
intervention. Drugs that block A~ binding to neuronal receptors and inhibit downstream 
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neurotoxic effects may offer a significant advantage over current therapies, since such 
compounds target the earliest molecular abnormalities in synaptic function. 
Recently, a novel and surprising candidate has emerged as a receptor for A~ 
oligomers, the cellular form of the prion protein (PrPc) [126]. PrPc, an endogenous, cell-
surface glycoprotein, plays an important role in transmissible neurodegenerative 
disorders such as Creutzfeldt-Jakob disease and bovine spongiform encephalopathy 
(commonly referred to as prion diseases) by serving as the substrate for formation of 
PrPsc, the infectious form ofPrP [71, 148]. A number of previous studies have shown 
that AB oligomers (but not monomers and fibrils) bind with nanomolar affinity to PrPc 
via two sites within the unstructured N-terminal tail at residues 23-27 and 95-105 [126, 
132]. A consequence of this interaction may be that PrPc transduces the synaptotoxic 
effects of AB oligomers [126]. Although some studies have challenged this conclusion 
. c [133, 141 , 142], others have confirmed that PrP could be targeted to block the effects of 
AB oligomers. For example, application of anti-PrP antibodies, or genetic ablation of 
PrPc, can prevent AB-induced synaptic dysfunction in hippocampal slices or transgenic 
mice [127, 129, 130, 132, 134, 139, 140]. Thus, PrPc could represent a novel 
pharmacological target in AD. 
Here, we combine the technologies of computer modeling and virtual screening 
with biochemical and biophysical binding assays to identify a high-affinity ligand for 
PrPc (called DS26) that inhibits A~-induced synaptotoxic effects on hippocampal 
neurons and slices. DS26 acts by blocking the interaction between A~ oligomers and 
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PrPc in an allosteric fashion. Our data provide novel insights into the molecular 
mechanisms ofPrPc-mediated signaling pathways, highly relevant in AD, prion diseases, 
and possibly other protein rnisfolding disorders that involve PrPc-mediated toxicity. 
3.3 Methods 
a. In Silica Analyses. 
(Experiments performed by Nunzio Iraci and Maria Letizia Barreca) 
i. Protein Preparation. The 20 nuclear magnetic resonance (NMR) PrPc 
conformations used in this study were retrieved from the RCSB Protein Data Bank (PDB 
code 1XYX [171]) and prepared using the Schrodinger Protein Preparation utility. The 
orientation of: hydroxyl groups on Ser, Thr, and Tyr; side chains on Asn and G1n; and 
the protonation state ofHis residues were optimized. N-and C-terminal residues were 
capped with acetyl and N-methyl groups, respectively. Steric clashes were relieved using 
an OPLS-2005 force field and a RMSD for non-hydrogen atoms of 0.30 A as 
convergence criteria [172]. 
ii. Site map analyses. The prepared structures were submitted to SiteMap to search 
for potential drug binding sites [173-175]. Reported sites were scored with the embedded 
SiteScore scoring function [176] , resulting in the identification ofPBD-1, which recurred 
with relatively high scores across all of the 20 NMR conformations. 
iii. Docking Grid Generation. Docking-based virtual screening simulations were 
performed using the Glide program [127]. The prepared NMR conformations were used 
as input to prepare the receptor grids. The grids were centered on the centroid of residues 
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134-137, 150, 154, 155, 157-160, 209,210, and 213, and the docking space was defined 
as a 24 A3 cubic box; the diameter midpoint of docked ligands was required to remain 
within a smaller, nested 14 A3 cubic box. No softening was used for the potential of 
nonpolar parts of the protein. 
iv. Ligands Preparation. The compounds tested in virtual screenings # 1 and #3 were 
processed through the LigPrep utility [ 1 77] to produce, starting from the 2D structure, 
low energy 3D structures taking into account ionization states, tautomers, 
stereochemistries, and ring conformations at the desired pH. For our study, a pH range of 
6-8 was set. 
v. Virtual Screening #1. For the pilot virtual screening which led to the 
identification ofDS5, 4 PrPc conformations were selected as docking targets (NMR 
conformations 4, 7, 8, 20). The selection was made on the basis oftheir SiteScore which 
accounts for number of site points, site enclosure, and hydrophilic/hydrophobic balance. 
Moreover, an additional theoretical structure, obtained by the minimization of the 
geometric average of all of 20 conformations, was used as a fifth target. Asinex Gold and 
Platinum libraries (Asinex, Moscow, Russia, www.asinex.com) (about 400,000 
compounds) were docked in parallel against the 5 target structures using Glide HTVS 
[178, 179]; the top 5% ranked docking poses were retrieved and advanced to Glide SP 
docking. Five percent of the Glide SP top scoring poses were docked and minimized 
using Glide XP. At this point, each set of 5- to 1 000-membered molecules obtained from 
one target was refined and rescored using GlideXP against the other 4 target structures. 
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A consensus score was calculated for each docked pose using the equation: 
score= {~=1 XPGscore( 1 +:A)} /n [180] , where n is the total number ofr target 
structures (5 in this case), XPGscore is the score assigned to the pose by Glide XP, and 
HA is the ligand heavy atom count. The XPGscore/HA term was included in the 
consensus score calculation in an attempt to overcome molecular weight related 
overestimation of binding energies. The 5 sets were then joined, duplicate molecules 
removed (keeping only the best scoring), and ranked by consensus score. 
vi. Virtual Screening #2. For the virtual screening that led to the identification of 
DS26 and DS40, all of the NMR conformations were used as docking targets. The ZINC 
database (standard purchasable chemical universe, [181]) was first screened in silica by 
using Glide HTVS, against 8 of the reported NMR confirmations. A post-docking 
constraint was applied to the retrieved compounds, i.e. only the molecules able to fit at 
least one non-hydrogen atom in a 5 A diameter sphere centered on the centroid of PBD-1 
were to be kept. The 10% GLIDE HTVS best scoring molecules were then docked 
though Glide SP against all of the NMR conformations and only the 10% best scoring 
docking poses in this analysis were retrieved; thus, sets of 20- to 4000-member docked 
molecules were obtained that had been refmed, rescored, and minimized using Glide XP 
against all of the target structures. Consensus scoring was calculated using equation 1. 
Using the Canvas program (Schrodinger Release 2013-1: Canvas, version 1.6, New 
York, NY, 2013) [182] , the ~80,000 resulting compounds were submitted to duplicates 
removal (keeping the best scoring duplicate only) and for the 10,000 highest scoring 
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compounds, mol2d 64 bits fmgerprints were calculated to achieve a diversity-based 
selection. After the molecular diversity filter and visual inspection of docking poses, 122 
compounds were selected for further analysis. These candidate compounds were 
submitted to molecular dynamics (MD) simulations performed by the MacroModel 
program [183]. Before running the MD simulations, all of the complexes were relaxed 
by 200 steps ofPolak-Ribiere conjugate gradient (PRCG) energy minimization. In this 
analysis, a simplified MD model was employed with the following specifications: i) 
MM-GB/SA was used as solvation treatment, ii) residues defining PBD-1 , residue 
comprised in a 2 A distance from PBD-1 , and residues 130-161 (tutto illoop) were set as 
fully flexible, iii) residues in a 3 A distance from the fully flexible set and not comprised 
in it were constrained by a 100 kcal/mol force, and iv) the remaining protein residues 
were kept frozen. RMSDs, for non-hydrogen atoms belonging to the fully flexible shell 
and for ligand non hydrogen atoms, were calculated as a function of the 20 ns simulation 
time. For each simulation, standard deviations (SD) were calculated for the RMSD time 
series to see whether a ligand was able to stay bound to the protein and to stabilize the 
flexible protein set. On the basis ofthese SD values, 51 molecules were finally selected 
for SPR assays [182, 183]. 
vii. Virtual Screening #3. The virtual screening workflow that led to the 
identification ofDS86 was based mainly on the protocol described for virtual screening 
#2. The two protocols differed only on a few points: i) the database to be screened was 
extracted from the whole e-molecules database and selection of 4000 molecules was 
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based on chemical similarity to DS26, as calculated by tanimoto coefficient applied to 
mol2d fingerprints; and ii) for the final selection, neither chemical diversity nor MD 
simulation filters were applied. 
viii. MD Simulations of Ligand-complexed PrPc. MD simulations were run in 
explicit solvent, using the TIP4P water model in a periodic boundary conditions 
orthorhombic box. Desmond molecular dynamics system (Schrodinger Release 2013-1: 
Desmond Molecular Dynamics System, version 3.4, Shaw Research, New York, NY). 
was used to setup and run the MD simulations [184]. The simulated environment was 
constructed using the system builder utility; structures were neutralized by Na+ and cr 
ions which were added to concentrations of 0.15 M. The buried regions were solvated 
using the "solvate pocket" utility [185]. Before performing the simulations, a series of 
minimizations and short MD simulations were carried out to relax the model system. The 
relaxation protocol consisted of six stages: (i) minimization with the solute restrained, 
(ii) minimization without restraints, (iii) simulation (12 ps) in the NVT ensemble using a 
Berendsen thermostat (1 0 °K) with non-hydrogen solute atoms restrained, (iv) simulation 
(12 ps) in the NPT ensemble using a Berendsen thermostat (10 °K) and a Berendsen 
barostat (1 atm) with non-hydrogen solute atoms restrained, (v) simulation (24 ps) in the 
NPT ensemble using a Berendsen thermostat (300 °K) and a Berendsen barostat (1 atrn) 
with non-hydrogen solute atoms restrained, and (vi) unrestrained simulation (24 ps) in the 
NPT ensemble using a Berendsen thermostat (300 °K) and a Berendsen barostat (1 atrn). 
At this point, 30 ns MD simulations were carried out at 300 °K in the NPT ensemble 
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using a Nose-Hoover chain thermostat and a Martyna-Tobias-Klein barostat (1.01325 
bar) [186, 187]. 
ix. Modelling ofPrP/DS26 Complex. The conformation ofDS26 was optimized 
with DFT calculations. Glide SP (Small-Molecule Drug Discovery Suite 2013-1 : Glide, 
version 5.9, Schrodinger, New York, NY). was used to dock DS26 against all ofthe 
NMR conformations; at most, 3 docking poses were retrieved for each target structure 
and poses were discarded as duplicates when RMS deviation was < 1.5 A and maximum 
atomic distance < 2.3 A. The set ofbound conformations for DS26 was then refmed, 
rescored, and minimized using Glide XP. The best docking pose was used to build the 
DS26/PrP complex. The DS26/PrP complex was relaxed using 100 steps of PRCG 
minimization with an OPLS-2005 force field and GB/SA solvation treatment [178, 179, 
188]. 
b. Expression and Purification of Recombinant PrP Molecules. 
See Chapter 2 methods (Section A) 
c. Surface Plasmon Resonance (SP R). 
See Chapter 2 methods (Section E) 
d. Equilibrium Dialysis. 
Seventy-five microliters of 50 ).lM compound and huPrP91-231 were placed in either 
chamber of a DispoEquilibrium DIALYZER (Harvard Appuratus, Holliston, MA) with a 
5,000 molecular weight cutoff. Sample was left to equilibrate at room temperature for 2 
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days with gentle rocking. After this time, the compound concentrations were quantified 
using UV -visible spectroscopy with the appropriate buffer or protein backgrounds 
subtracted. 
e. Fluorescent Polarization. 
Samples containing recombinant C-PrP (120-230) were mixed with DS104 and 
allowed to equilibrate for 60 minutes. Fluorescent polarization was measured on a 
Synergy H1MF plate reader (Biotek, Winooski, VT) fitted with a 485 nm excitation filter 
and 528 nm filter in both the parallel and perpendicular polarization light paths. 
Polarizations values were calculated using the Synergy Gen 5 software (Biotek Winooski, 
VT) and expressed in millipolarizaiton units (mP). 
f Circular Dichroism and Thermal Stability Assay. 
CD spectra were collected using a Jasco J-815 spectropolarimeter equipped with 
thermoelectric temperature controllers (Jasco Inc., Japan). Alpha helical content of the 
protein was monitored at a wavelength of 220 nm. A temperature ramp rate of 1.0 
°C/min was applied from 25 to 95 °C. Thermal unfolding curves were measured in the 
presence or absence of 1 00 ~M of DS26, or equal volume of buffer. The curves were 
smoothed using Sigma Plot (Systat Spftware, San Jose, CA) software. The melting 
temperature (Tm) for each sample was determined from the first derivative of the melting 
curve. 
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g. Tryptophan Fluorescence Detection. 
Tryptophan fluorescence data were collected using a Synergy H1MF (Biotek 
Winooski, VT). PrP (5 uM) was incubated with various concentrations ofDS26 or DS15 
for 1 hour before fluorescence measurements. The samples were excited at 278 nm and 
emission spectra were collected from 300 to 450 nm using a monochromator light path. 
Values represent an average of 3 replicate wells. 
h. Immunoprecipitation Assay. 
See Chapter 2 methods (Section D) 
i. Enzyme-linked immunosorbent assay (ELISA) 
ELISA was done as described previously [130] . ELISA plates were coated with 
recombinant PrP in binding buffer (10 rnM sodium carbonate, pH 9.6) overnight. The 
plates were blocked with BSA for 1 hour. Different concentrations ofDS26 were 
incubated in PBST buffer for 1 hour. After washing A~ oligomers were incubated for 1 h. 
The level of A~ oligomer binding was detected using an anti- A~ antibody, 6E10, 
followed by anti-mouse-AP antibody, and NBT/BCIP. The absorbance was read at 
405nm on a Biotek Synergy platre reader. Plates were incubated for 1 hour at each step 
and washed with PBST between steps. 
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3.4 Results 
a. Identification of High Affinity Ligands for PrPc. 
The first step in identifying small molecule ligands for PrPc was to defme 
potential binding sites on the C-terminal structured domain of the protein. We employed 
SiteMap software [189] to scout the surface of20 different NMR conformations of 
mouse PrPc (PDB 1XYX). This analyses identified a binding region on the surface of 
PrPc, named PrP-binding domain 1 (PBD-1), defined by twelve, non-continuous residues 
(134-137, 150, 154, 155, 157-160, 209, 210, 213) which were recurrent in all ofthe 
conformations of the protein (Figure 19). 
To identify high affmity ligands for PrPc, we performed a pilot virtual screening 
(see Methods, Virtual Screening #1) against the PBD-1 pocket using the Glide program 
[178, 179]. This study was performed on a small database of commercially available 
molecules ( 400,000 compounds) using four conformations of PrPc as targets; the 
conformations were selected on the basis of their sitemap scores for the PBD-1 pocket 
and the average of all 20 different NMR conformations. The three best scoring 
compounds were then tested in vitro for binding to PrPc by surface plasmon resonance 
(SPR), a label-free technique that allows estimation of kinetic and binding constants for 
protein-ligand interactions [190]. Recombinant, mouse PrPc was immobilized on the 
surface of a SPR chip, as confirmed by binding of an anti-PrP antibody (D 18, Figure 
20G), and each small molecule flowed over the PrPc protein layer. As shown in Figure 
20A, we detected specific binding of one molecule, designated DS5 [2R,3S,4S,5S,6R)-2-
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(hydroxymethyl)-6-[(3-hydroxyphenyl)amino ]tetrahydro-2H-pyran-3,4,5-triol], to PrPc at 
an estimated affmity in the micromolar range (KD = 10 )lM). This result provided 
experimental evidence that the PBD-1 could be targeted to identify PrPc ligands. 
To expand our initial results, we designed a more sophisticated protocol (see 
Methods, Virtual Screening #2) to screen a larger database of commercially available 
compounds (ZINC all purchasable set, ~ 17 million molecules) against the PBD-1 pocket 
in all of the different NMR conformations ofPrPc. Compounds predicted to bind the 
PBD-1 site were filtered by molecular diversity and visual inspection, and prioritized by 
MD to predict the stability of each protein-ligand complex. A schematic of the workflow 
is shown in Figure 19A. These analyses identified 52 candidate molecules. Among 
these, 16 were available in the compound library ofthe National Cancer Institute, and 
were tested for binding to PrPc by SPR. Two molecules, called DS26 [2-(2R,3S,5R,6S-
pentahydroxycyclohexylidene) hydrazinecarbothioamide] and DS40 [3R,4S-dihydroxy-
5S-(1,2,3-trihydroxypropyl) dihydrofuran-2(3H)-one] showed sub-micromolar affinity 
for PrPc (Figure 20B,C) by SPR with KD = 0.51 )lM and 0.86 )lM, respectively. A 
docking pose of DS26 attached to PBD-1 is shown in Figure 19C. 
Additional candidate ligands for PrPc were selected by in silica screening of 
DS26-like molecules (see Methods, Virtual Screening #3). Six of these compounds were 
analyzed by SPR and one additional PrPc ligand, DS86 [(1S,2R,3R)-1-(1H-tetrazol-5-
yl)butane-1,2,3,4-tetrol], was identified (Figure 20D). The binding affinity ofthis 
compound was estimated to be in the micromolar range (KD = 4 )lM). We failed to 
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observe detectable binding (KD > 1mM) of GN8 or quinacrine, two anti-prion compounds 
with reported affinities for PrPc (Figure 20E, F) [191]. Among the four newly identified 
PrPc ligands, DS26 showed the highest affinity for PrPc. Binding of this molecule to 
PrPc was also characterized by remarkably slow dissociation kinetics (Koti) (Figure 20H). 
Based on these properties, DS26 was chosen as the lead compound in all subsequent 
experiments. 
b. DS26 undergoes Multi-step Dissociation from PrPc. 
The dissociation of DS26 was not well fitted using a simple Langmuir model 
(Figure 21A). Specifically, the first 3 minutes of buffer wash following DS26 injection 
showed a faster dissociation compared to the rest of the wash, suggesting a multi-state 
dissociation. To examine how the koff rate changes during dissociation, we constrained 
the Langmuir model analysis to specific time points during a 10 hour wash following a 
50 ).lM injection DS26. Dissociation (koff) and estimated half-life (t112) results for the 
different time intervals were: 0-200 seconds, koff of 3.95 x 104 s-1 and t112 = 29 minutes 
(Figure 21C); 6-20 minutes, koffof7.46 x 10-5 s-1 and t112 = 2.6 hours (Figure 21D); 30-60 
minutes, koffof7.21 x 10-6 s-1 and t112 = 26.7 hours (Figure 21E); 4-8 hours, koffof 1.71 x 
10-6 s-1 and estimated t 112 = 112.6 hours (Figure 21F); and 9-10 hours, koffof6.89 x 10-7 s-
1 and t112 = 279 hours (Figure 21 G). The t112 was calculated using the following equation: 
h ; . = ln(z) [192]. The slow dissociation suggests the possibility of a covalent bond 
6 Koff 
between DS26 and PrPc. However, mass spectroscopic analysis did not show a 
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characteristic 2 hydrogen loss expected when a covalent bond is present in the DS26-
PrPc complex (data not shown). 
c. Single Isomer of DS26 Binds Specifically to PrPc. 
Mouse PrP (PBD file lXYX) was used in both the in silica and initial SPR 
screenings. To confirm that DS26 bound to human PrP (hPrP), we generated 
recombinant hPrP 23-230 and measured DS26 binding using SPR. We observed 
identical binding ofDS26 to moPrP and hPrP (Figure 22A). In addition, we were unable 
to detect specific binding to bovine serum albumin (BSA), myoglobin, or to the chip 
surface (Figure 22B-D) suggesting that DS26 is a specific ligand for PrPc. We also 
observed that DS26 binds to PrPc under a wide range ofbuffer conditions from pH 7.2 to 
4.0 (Figure 23). 
In aqueous solution, DS26 can spontaneously form two distinct isomers as 
identified by NMR and designated as E and Z forms (Figure 24A). DS26 samples were 
enriched for either isomer and binding to PrP was measured by SPR. We found only one 
isomer, bound specifically to PrPc suggesting stereospecificity to the DS26 binding 
pocket (Figure 24B). After allowing both samples to equilibrate overnight with heating 
at 37 °C, we found similar binding kinetics between the two isomers (Figure 24C). 
d Validation of DS26 as PrPc Ligand 
To-further confmn binding ofDS26 to PrPc, we employed several alternative 
techniques. First, we tested binding of this compound to PrPc by equilibrium dialysis 
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(EQD), a simple method based on the ability of small molecules to equilibrate between 
two chambers: one containing the target protein (sample chamber) and one that is empty 
(assay chamber) with a membrane permeable only to small molecules separating the two 
(see Figure 25A). As expected, DS26 equilibrated equally between the two chambers 
when the sample chamber contained BSA or buffer alone. Conversely, when 
recombinant PrPc (50 J..LM) was added to the sample chamber, we observed a 75% 
decrease in the concentration of DS26 in the assay chamber, indicating that the 
compound was retained by PrPc in the sample chamber. [Fe(III)-TMPyP; abbreviated 
TP] , a cationic porphyrin previously reported to interact with PrPc, served as a positive 
control for the EQD assay [191]. No interaction was observed for GN8 or DS15 (Figure 
25B), molecules that also failed to bind PrPc by SPR. 
Next, we engineered a fluoresceinated derivative ofDS26 (referred to as DS104, 
Figure 26A). The binding affinity of this molecule to PrPc, as evaluated by SPR, was 
lower than that ofDS26 (KD = 4 J.!M, Figure 26B). We utilized the fluorescent properties 
of DS 104 (excitation 480 nm, emission 520 nm, Figure 26C) to confirm binding in 
solution with PrPc by fluorescent polarization (FP). FP is a technique that measures the 
polarization of light caused by a fluorophore when free or bound to a larger ligand [ 193]. 
We incubated DS104 with increasing amounts ofPrPc and observed a concentration-
dependent increase of polarization, indicating that the compound was binding to the 
protein (Figure 27 A). The curve was fitted using a single binding site, saturation receptor 
model in Graph Pad (GraphPad Prism v6, GraphPad Software, San Diego California 
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USA, www.graphpad.com [192]); the Ko was calculated to be 4 uM +/- 0.3 J.!M. We did 
not observe binding of DS 104 to BSA or myoglobin (Figure 27B). DS26 is structurally 
similar to an AD pharmaceutical currently in clinical trials, scylla-Inositol (ELND005) 
which is thought to bind A~ oligomers and inhibit aggregation [ 194]. We found that 
DS 1 04 did not bind to A~ oligomers at concentrations of the protein up to 1 00 J.!M 
(Figure 27C). Next, we used our FP assay to test the ability of other PrPc ligands to 
compete with DS104 for binding to PrPc. We found that DS26, DS5, and DS40, but not 
GN8 or DS 102, were able to displace DS 104 from PrPc (Figure 27D). These results 
confirmed that DS26 binds to PrP in solution. Additionally, DS26 and the other 
compounds, identified in silica, share the same binding pocket on PrPc. 
e. DS26 Blocks Prion Conversion. 
Based on the conclusion that DS26 is a novel PrPc ligand, we sought to 
characterize the biological properties of this compound. In principle, any small molecule 
ligand for PrPc could act as a pharmacological chaperone and stabilize the native 
structure of the protein, preventing its misfolding into the infectious form, PrPsc. To test 
this hypothesis, we ran MD simulations ofPrPc alone (PDB 1XYX) or in complex with 
DS26 or anti-PrP antibody, ICSM-18 (PDB 2W9E). In experiments done by Nunzio 
Iraci and Maria Letizia Barreca, we found that both ICSM-18 and DS26 decreased the 
intrinsic motion ofPrPc, although the antibody showed a much stronger stabilization 
effect (Data not shown). These data supported the notion that DS26 could stabilize the 
native structure ofthe globular domain ofPrPc. To verify this assumption in vitro, we 
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employed circular dichroism (CD) in a thermal-denaturation assay, which was previously 
used to characterize potential PrPc ligands [191]. This assay is based on the principle 
that protein folding and ligand binding are thermodynamically linked. Thus, binding of a 
ligand could increase the temperature at which the target protein denatures. We initially 
determined the thermal stability ofthe C-terminal domain ofPrPc by CD, monitoring the 
presence of alpha helices at 220 nm (Figure 28A). The observed Tm for PrPc was 66.8 
°C. In presence ofDS26, the Tm value increased to 68.9 oc (Figure 28B). Thus, it 
appeared that binding ofDS26 stabilized the native folding ofPrPc. 
Next, we directly tested whether DS26 could interfere with the conversion ofPrPc 
into PrPsc. In experiments done by Tania Massignan, a clone of murine neuroblastoma 
cells (N2a.3), previously selected for their high susceptibility to prion infection 
(unpublished data), was infected with the rocky mountain laboratory (RML) prion strain 
and propagated the line for 5-7 passages to stabilize PrPsc levels (not shown). We then 
exposed RML-N2a cells to different concentrations ofDS26 (10-500 ~-tM) or vehicle 
control for 72 hours and measured the levels of proteinase K-resistant PrPsc by 
immunoblot. We found that treatment with DS26 reduced PrPsc levels in RML-N2a 
cells, in a dose-dependent fashion (Data not shown). Collectively, these data indicate that 
DS26 is an anti-prion compound, likely acting as a pharmacological chaperone for PrPc. 
f DS26 Inhibits Effects of AfJ Oligomers in Brain Slices. 
In addition to its role in prion diseases, PrPc has recently been identified as a 
toxicity-transducing receptor for A~ oligomers, which are believed to be responsible for 
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the synaptic dysfunction and cognitive decline occurring in patients with AD [126, 195]. 
Thus, we sought to test whether DS26 could inhibit the neurotoxic effects of A~ 
oligomers. To substantiate the anti-A~ effects ofDS26, we turned to electrophysiological 
measurements of long-term potentiation (LTP) in mouse hippocampal slices. L TP in the 
hippocampus is believed to be the mechanism by which memories are encoded into 
neuronal networks [196]. In experiments done by Jennifer Helfer, a single, brief theta-
burst stimulation (TBS) in the Schaffer collateral pathway between hippocampal CA3 
and CAl regions is sufficient to trigger LTP in C57/Bl6 mice (161.35 ± 4.6, n = 11) 
(Data not shown). Incubation with A~ oligomers (500 nM) significantly suppressed LTP 
(117.2 ± 5.4, n = 12, p < 0.01), an effect that is dependent upon the expression ofPrPc 
(Prnp010 mice: 143.3 ± 3.0, n =10; Prnp0/0 slices treated with A~: 145.6 ± 7.9, n =8). In 
order to test whether treatment with DS26 could lessen the effects of A~ oligomers on 
LTP, we perfused the samples with DS26 (100 f!M) for 20 minutes prior to A~ 
application. DS26 was able to diminish the effect of A~ oligomers (142.3 ± 5.2, n = 11). 
No change in LTP was detected when DS26 was administered to either WT or Pmp010 
slices (Figure not shown). Collectively, these results demonstrate that DS26 blocks the 
PrPc-dependent effects of A~ oligomers on LTP. 
g. DS26 Blocks Interaction between AfJ Oligomers and PrPc in Allosteric Fashion. 
One plausible mechanism by which DS26 rescues cells from the toxic effects of 
A~ oligomers may involve inhibition of interactions with PrPc. To test this hypothesis, 
we used a cell-based assay that measures the binding ofbiotinylated A~ oligomers to 
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cells expressing PrP. In experiments done by Kelli Cox, we observed a dose-dependent 
binding of A~ oligomers to PrPc transfected cells; the K0 was calculated to be 1 00 nM. 
Vector transfected cells did not show specific binding. We found that treatment with 
DS26 caused a dose-dependent decrease in A~ oligomers binding with an estimated half 
maximal inhibitory concentration (IC50) of 50 nM (Data not shown). 
To further dissect the mechanism by which DS26 inhibits A~ binding to PrPc, we 
immuno-captured recombinant mouse PrPc on the surface of a SPR chip and evaluated 
the binding of A~ oligomers in the presence of increasing compound concentrations. We 
found that DS26 inhibited binding of A~ oligcimers to PrPc in a dose-dependent fashion 
(Figure 29A). Two distinct A~ oligomer binding sites have been identified on PrPc 
(residues 23-27 and 95-1 05) [132]. These sites are both encompassed within the flexible, 
N-terminal tail ofthe molecule (residues 23-111). Conversely, DS26 is predicted to bind 
a conformational pocket located at the C-terminus in a globular domain (residues 120-
230). To confirm that A~ oligomers and DS26 bind in two different regions ofPrPc, we 
immobilized recombinant mouse PrPc or two fragments, corresponding to theN-terminal 
(23-111 , N-PrP) or C-terminal (120-230, C-PrP) regions, onto the surface of separate 
SPR chips. We found that A~ oligomers bind to both PrPc and N-PrP, but not to C-PrP. 
Conversely, C-PrP was necessary and sufficient for binding to DS26 (Figure 29B). 
These data confirmed that DS26 and A~ oligomers bind in two different regions of PrPc. 
Consistent with this conclusion, DS26 failed to inhibit the binding of A~ oligomers to N-
PrP (Figure 29C). Collectively, these results indicate that the ability ofDS26 to inhibit 
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binding of A~ oligomers to PrPc is not exerted by direct competition, but through an 
unexpected allosteric effect. 
Our SPR could be limited by the lack of equilibrium between DS26 and A~ 
oligomers. To confirm the SPR results, we used an enzyme-linked immunosorbent assay 
(ELISA), an equilibrium binding assay, to confirm the effects ofDS26. In this analysis, 
we observed binding of A~ oligomers to PrPc with a calculated K0 of 28 nM (Figure 
30A). Next, we measured the inhibition of binding of A~ oligomers to PrPc by DS26. 
We found a DS26 dose-dependent decrease in the amount of A~ oligomers captured by 
PrPc with an IC50 of 15 J.LM. Incubation ofDS26 before or during the addition of A~ 
oligomers did not affect the calculated IC50 (Figure 30B). Interesting, the addition of 
DS26 after A~ oligomers were bound to PrPc did not release A~ oligomers from PrPc 
(Figure 30C). 
h. DS26 Promotes Interaction between N-and C-terminal Domains ofPrPc. 
To gain additional insights into the mechanism ofDS26-mediated allosteric 
inhibition, we tested whether this compound induces a conformational change in PrPc. 
By far-UV CD, we did not observe any substantial change in the secondary structure of 
PrPc when DS26 was present and assumed bound to the protein (Figure 31A). These 
data imply that the effect of DS26 on PrPc is not exerted by altering the overall 
conformation of the globular domain of the protein. We were unable to perform near-
UVNis CD to examine changes in the tertiary structure ofPrPc because the absorbance 
of DS26 occurs in this spectral region. 
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We then tested the effect ofthe DS26 on theN-terminal domain ofPrPc. This 
unstructured, flexible region (23-111) of the protein contains 7 of 8 tryptophan (Trp) 
residues found in the mature protein. Trp has a maximum absorption at 280 nm and a 
maximum emission typically between 300-350 nm. Several unique and advantageous 
characteristics ofTrp are: emission is solvatochromic, fluorescence can vary with 
changes in polarity of the local environment, and proximity of other residues (such as 
aspartic acid and glutamic acid) can cause quenching [197]. These properties allow 
measurement of the conformation of PrP by detecting changes in Trp fluorescence. 
When excited at 280 nm, full-length recombinant PrPc produces an emission peak at 345 
nm. Interestingly, incubation with DS26 caused a dose-dependent quenching of the 
signal (Figure 31B). Conversely, DS15, a small molecule with an absorbance spectrum 
similar to DS26 but no detectable affinity for PrPc, did not produce any change in the Trp 
fluorescence ofPrPc (Figure 31C). Furthermore, the fluorescence ofN-PrP alone was 
unaffected by DS26, ruling out the possibility that the absorbance of DS26 was 
interfering with our detection of the Trp fluorescence signal (Figure 31D). These results 
suggest that binding ofDS26 in the C-terminus ofPrPc alters the conformation ofthe 
flexible N-terminus. This conclusion could imply that the drug promotes the interaction 
ofthe N-terminal tail with the globular domain ofPrPc. To test this directly, we co-
immunoprecipitated C-PrP in the presence or absence ofDS26 using a myc-tagged N-
PrP. We observed co-immunoprecipitation of the two PrP fragments only after 
incubation with DS26 (Figure 32A). These data were further confirmed by SPR 
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experiments in which myc-tagged C-PrP was captured on the surface of a chip and N-PrP 
was passed over the protein. We found that N-PrP interacted with C-PrP only after pre-
injection ofDS26 (Figure 32B). These results demonstrate that binding ofDS26 
promotes an interaction between theN- and C-terminal ends ofPrPc. 
i. DS26 is a Functional Inhibitor of PrPc. 
We hypothesized that the effect ofDS26 on the conformation of the flexible N-
terminus ofPrPc could directly influence some activity ofthe protein. Unfortunately, the 
physiological activity ofPrPc is poorly understood and structure-function assays are 
limited. We have previously reported that mutations in the conserved central region of 
PrPc caused toxic ion channel activity that is likely related to the normal function ofthe 
protein [87, 88, 198]. These aberrant ionic currents, which can be detected in cells by 
patch-clamping techniques, require the poly-basic N-terminal domain [199-201]. Here, 
we tested whether DS26 inhibited the channel activity of the most active PrP mutant, i.e. 
one lacking the entire central region, ~CR PrP. First, we confirmed by SPR that DS26 
binds to ~CR PrP (Figure 33A). Next, in experiments done by Isaac Solomon, 
we performed whole-cell patch-clamp recordings of HEK293 cells stably transfected with 
either WT or ~CR PrP. As expected, cells expressing ~CR PrP, but not WT controls, 
exhibited large, spontaneous inward currents (data not shown). Importantly, treatment 
with DS26 (20 ~M) completely silenced ~CR PrP-induced currents (Data not shown). 
The inhibitory activity of DS26 was irreversible, as the currents were still silenced for 
several minutes after removing the compound from the solution. These results were 
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consistent with data obtained by MD and SPR which indicated that DS26 has particularly 
slow dissociation kinetics from PrPc. 
j. P KIP D studies of DS26 in mice. 
We next measured the pharmacokinetic/pharmacodynamic (PKJPD) properties of 
DS26 in mice. In experiments done with a contract research organization, DS26 was able 
to enter the blood stream with oral administration and the oral bioavailability was 
measured at 6.5%. However, DS26 could not be detected in mouse brain after oral 
administration and only 0.7% ofDS26 was able to penetrate the blood brain barrier with 
intravenous (IV) administration (Data not shown). 
In summary, our data support a model by which DS26 induces an auto-inhibitory 
change in PrPc caused by the conformational rearrangement of theN-terminal, flexible 
tail onto the C-terminal globular domain of the protein. As a result, the compound 
abrogates binding of A~ oligomers to theN-terminus ofPrPc and acts as a functional 
inhibitor of the toxic PrP mutant that relies on theN-terminus to elicit ionic currents. It is 
possible to speculate that DS26 mimics an endogenous ligand that modulates the 
physiological activity of PrPc, or its ability to elicit toxic signaling. 
3.5 Discussion 
We identified DS26, a small molecule that inhibits the neurotoxicity of A~ 
oligomers by targeting PrPc. The compound was discovered by virtual screening 
analyses and its affinity for PrPc was estimated by biochemical and biophysical binding 
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assays. We showed that DS26 prevents A~-dependent suppression ofLTP in 
hippocampal slices. The small molecule operates by an unusual allosteric mechanism in 
which ligand binding to a site in the structured C-terminal half of PrPc induces an 
intramolecular interaction with theN-terminal tail, thereby preventing A~ binding. Our 
data validate PrPc as a pharmacological target in AD. The chemical nature ofDS26 and 
its mode of action suggest the existence of an endogenous ligand that regulates PrPc 
activity by altering the conformation of the flexible N-terminus. 
a. DS26 as an Anti-Af3 Molecule. 
The recent identification of PrPc as a potential receptor for A~ oligomers has led 
to an increased effort to characterize the effects of this interaction at a functional level. 
Ablation of PrPc or the use of antibodies directed against the protein was shown to 
diminish the neurotoxic effects of A~ oligomers in hippocampal slices and transgenic 
mice [126-128, 130, 131]. However, a number of conflicting results have left the 
question of whether PrPc is essential for transducing the toxicity of A~ oligomers 
unsettled [133 , 141 , 142]. Our data adds a pharmacological perspective that helps to 
resolve the discrepancy between previous studies. We showed that the A~-dependent 
effects on synaptic integrity and hippocampal L TP are suppressed by a small molecule 
directed against PrPc that blocks interaction with the oligomers. Our results may have 
important therapeutic implications as the data provide strong experimental evidence that 
PrPc could be targeted to suppress A~ toxicity. In fact, in contrast to existing therapies 
for AD, most of which aim to reduce the levels of toxic A~ or tau species, DS26 has the 
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potential to directly block the proximal events leading to synaptic dysfunction and 
degeneration activated by A~ oligomers. 
Compounds like DS26 may be capable of halting the neurodegenerative process 
even after substantial amounts of A~ have already been deposited in the brain. This 
feature is highly desirable, since recent evidence indicates that A~ levels in the brains of 
AD patients begin rising many years prior to the onset of clinical symptoms [168]. Thus, 
it may be possible to administer DS26 at a time when the earliest, mildest symptoms 
appear in a patient, thereby arresting the slow, inexorable, cognitive decline that is typical 
in AD. DS26, administered pre-symptomatically, may be effective in completely 
preventing development of clinical features, particularly if given in combination with A~­
lowering therapies. Finally, PrPc -directed therapeutics like DS26 are likely to have fewer 
side effects than some other agents (e.g., secretase inhibitors) which act on molecular 
targets that perform other essential biological functions. In fact, genetic deletion of the 
PrPc gene has no observable phenotypic effect in mice or cattle [89]. 
DS26 is unlikely to be used directly as a therapeutic agent due to its chemical 
properties. Most orally active drugs are small lipophilic molecules with common 
properties as generalized in Lipinski's Rule of 5 [202]. The rule states that the majority 
of orally active drugs have: a) no more than 5 hydrogen bond donors, b) no more than 10 
hydrogen bond acceptors, c) a molecular weight less than 500 daltons, and d) an octanol-
water partition coefficient no more than 5 [202-204]. DS26 violates Lipinski's Rule with 
8 hydrogen bond donors, the majority of which are located in the inositol ring. We have 
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observed the poor absorption, distribution, metabolism, and excretion (ADME) 
pharmacokinetic properties in mice. Further development of DS26 will require extensive 
structure-activity relationship (SAR) studies which would likely involve altering the 
inositol ring. While more drug design studies are necessary, this work clearly 
demonstrates that the PBD-1 pocket on PrPc is a therapeutic target for AD. 
b. DS26 as an anti-Prion Compound. 
Our approach centered on the idea of identifying small, high-affinity ligands for 
PrPc. A number of compounds active against PrPsc replication in cells have previously 
been proposed to act by targeting PrPc [205] . Examples include sulphated glycans (such 
as pentosan polysulphate and cyclodextrins) [206, 207], cyclic tetrapyrroles (porphyrins 
and phthalocyanines) [208], the anti-malaria drug quinacrine [209] , and a small molecule, 
known as GN8, discovered using an in silica approach similar to the one described herein 
[210, 211] . These compounds have been shown to possess either poor specificity or low 
affinity for PrPc, with the exception of GN8 which was reported to bind PrPc with 
micromolar affinity [211 , 212] . However, in our studies, we failed to detect binding of 
GN8 to PrPc by either SPR or EQD. Our observations are consistent with other recently 
published data [191]. Conversely, we showed by multiple techniques that DS26 binds 
stereo-specifically to the C-terminus ofPrPc with sub-micromolar affinity. This 
compound represents the first member of a novel generation of small, high-affinity 
ligands for PrPc. 
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We found that DS26 inhibits PrPsc replication in cell cultures, in a dose-
dependent fashion. An explanation for this activity is that the compound blocks the 
interaction between PrPc and PrPsc similar to the effect seen with A~ oligomers. Indeed, 
the ability ofDS26 to promote the interaction between theN- and C-terminal ends of 
PrPc could directly disfavor binding to PrPsc. This possibility is consistent with our 
recent observation that a poly-basic domain in theN-terminus ofPrPc determines the 
efficiency of prion propagation by participating in the initial steps of formation of the 
PrPc-PrP8c complex [80]. Our analyses using MD and CD thermal denaturation indicate 
that the compound also acts as a pharmacological chaperone, stabilizing the folded state 
ofthe globular domain ofPrPc. In this case, an anti-prion effect could be exerted by 
reducing the Gibbs free energy (L).G) of the PrP polypeptide causing a consequent 
increase of the activation energy (Ea) necessary for reaching any unfolded state along the 
pathway of PrP8c formation. A similar mechanism has already been proposed for 
explaining the anti-prion effect ofFe(III)-TMPyP (TP), a cationic porphyrin previously 
reported to interact with PrPc [191]. Our data imply that a second ligand, binding with 
similar affinity but to a different pocket in PrPc, could act synergistically with DS26 and 
stabilize the native folding enough to completely block the formation ofPrP8c. Thus, a 
cocktail of two or three such PrPc ligands could show unprecedented therapeutic effects 
against prion diseases. 
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c. Dissecting the Mode of Action for DS26. 
One of the striking findings of our study is that DS26 induces an auto-inhibitory 
interaction between theN-terminal tail and the structured C-terminal end ofPrPc. This 
mechanism explains some of the biological properties of the compound, i.e. inhibition of 
both A~ oligomer binding and ionic currents induced by .6.CR PrP. DS26 was shown to 
modulate binding of A~ oligomers to PrPc. The inhibition of binding was further 
demonstrated in cells and blocked the A~ oligomer-induced suppression of L TP in 
hippocampal slices . .6.CR PrP exerts its neurotoxic effects with the polybasic domain in 
theN-terminus ofthe PrP (residues 23-31; KKRPKPGGW) [76-80]. This region, which 
has been linked to several cell biological properties ofPrPc, is believed to promote the 
insertion of theN-terminus of .6.CR PrP into the plasma membrane; a consequence of this 
is the formation of transient pores that cause spontaneous ionic currents which can be 
detected by patch clamping techniques. DS26 blocked the spontaneous ionic currents, 
providing further evidence that the binding of DS26 promotes an interaction between the 
N-and C-terminal ends ofPrPc. 
d. Natural Ligands of PrPc. 
Our study ofDS26 is the first observation that theN-terminus ofPrP can interact 
with the C-terminus after ligand binding. One explanation of this interaction is that it is 
an artifact of DS26 binding. It is also conceivable that DS26 is related to natural ligands 
that bind to the PBD-1 domain which plays an important role in prion biology. In fact, 
the structure of DS26 is similar to several natural inositol derivatives involved in cell 
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signaling. Further studies are needed to identify any natural ligands of PrP and precisely 
define their role in modifying PrP activity. These natural ligands could provide insight 
into the normal function of PrP. 
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Figure 19. In silico identification of PrPc ligands. 
(A) Schematic of in silica screen. Seventeen million compounds from the ZINC database 
were screened for binding to PrPc (PDB file 1XYX) using the Schrodinger Glide 
program with the HTVS docking algorithm [178, 179]. Compounds were then screened 
using the SP and XP docking algorithm. Hits were further refined with visual inspection 
and ranked using MD. The in silica screening generated 52 possible ligands for PrPc. 
(B) Structure of the Prion Protein (lXYX) with the PrP-binding domain 1 (PBD-1) site 
highlighted in yellow. (C) Schematic ofPBD-1 with the lead compound, DS26, docked 
in the binding site. 
(The computer modeling was done by Nunzio Iraci and Maria Letizia Barreca.) 
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Figure 20. SPR-based evaluation of binding to PrPc. 
Different concentrations of (A) DS5, (B and H) DS26, (C) DS40, (D) DS86, (E) GN8, (F) 
quinacrine, and (G) anti-PrP antibody D18 were injected for 3 min over sensor surfaces 
on which 17,000 RU ofPrPc had been previously captured by amine coupling. 
Sensorgrams show small molecule binding in resonance units (RUs). (A) DS5, (Band H) 
DS26, (C) DS40, (D) DS86, and (G) D18 bind to PrPc. No specific binding was detected 
for (E) GN8 or (F) quinacrine. The data were fitted using the Langmuir equation, 
modeling a simple bimolecular interaction as indicated by the black line. Estimated 
affinities were: KD = 10 x 10-6 M for DS5 (A), KD = 0.5 x 10-6 M for DS26 (B), KD = 0.8 
x 10-6 M for DS40 (C), KD = 4 x 10-6 M for DS86 (D), and KD = 62.3 x 10-9 M for D18 
(G). The predicted half-life ofDS26 (H) is 19.6 hours with an offrate of9.81 x 10-6 s-1, 
generated using a two-state model of dissociation. 
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Figure 21. Characterization of DS26 dissociation. 
50 ~-tm ofDS26 was injected for 3 min over sensor surfaces on which 17,000 RU ofPrPc 
had been previously captured by amine coupling. Sensorgrams show small molecule 
binding in resonance units (RUs). The data was fitted (solid line) using either (A) the 
Langmuir equation, modeling a simple bimolecular interaction, or (B) a two-state model, 
modeling two state dissociation. To further understand the multi-rate dissociation, we 
constrained the Langmuir model to (C) the first 200 seconds, (D) 6 to 20 minutes, (E) 30 
minutes to 1 hour, (F) 4 to 8 hours, and (G) 9 to 10 hours. We found that the koti rate 
slowed as time of dissociation increased. Half-lives (t112) were calculated using the koti 
values. 
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Figure 22. DS26 binds specifically to human PrPc. 
Different concentrations of DS26 were injected for 3 min over sensor surfaces on which 
17,000 RU of human PrPc had been previously captured by amine coupling. 
Sensorgrams show small molecule binding in resonance units (RUs). (A) DS26 bound to 
human PrP (hPrP) in a dose-dependent manner. There was no detectable binding to BSA 
(B), myoglobin (C), or the chip surface (D). 
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Figure 23. DS26 binds to PrPc under a wide range of buffer conditions. 
Different concentrations ofDS26 were injected for 3 min over sensor surfaces on which 
17,000 RU ofPrPc had been previously captured by amine coupling. Sensorgrams show 
small molecule binding in resonance units (RUs). DS26 bound to mouse PrP (moPrP) in 
(A) PBS, pH 7.4; (B) 10 mM phosphate, pH 6.0; (C) 10 mM acetate, pH 5.0; and (D) 10 
mM acetate, pH 4.0. 
128 
PSS 
pH7.4 
10mM Phosphate 
p'H 6 ,.() 
lOmM Acetate 
pH5.0 
lOmM Acetate 
pH 4 . 0 
moPrP 2.3-230 
~ ~ ~ ~ ~ ~ ~ D ~ 
TI!!M·{I) 
·Ji.i:l · ;Jf.fJ ·l~ '.! :4!} m • );IQ· ·<i;lil !RlQ ·l!lQ ;w ~· ~· 
TIIM{IIj 
i ~~- : ~~.~~ .- ; ' -~.  
-~ ·•.Mt' .(t~· a. :!!l!l h'l<l :!!ill ·;f(J(> tw ~ ~· n • m 
-<•1 
129 
• t OOuM 
OSOuM 
•25uM 
Ol2.5.uM 
Figure 24. A single isomer ofDS26 binds to PrPc. 
In aqueous solutions, DS26 equilibrates to form two different isomers. (A) Chemical 
structures of the two isomers ofDS26. (B) Samples were emiched for either theE or z 
stereoisomer and injected for 3 min over sensor surfaces on which 17,000 RU ofPrPc 
had been previously captured by amine coupling. Sensorgrams show small molecule 
binding in resonance units (RUs). Only one isomer, had detectable binding to PrPc. The 
"active" isomer is clearly distinguishable due to its brown color. (C) After overnight 
equilibration, both isomers showed similar binding to PrPc and color. 
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Figure 25. Validation ofDS26 binding to PrPc by EQD. 
Equilibrium dialysis (EQD) is a simple method based on the ability of a small molecule 
to equilibrate between two chambers, one containing the target protein (referred to as 
sample chamber) and one empty (assay chamber), separated by a membrane permeable 
only to the small molecule. (A) A schematic of the EQD experiment. (B) DS26 
equilibrated equally between the two chambers when the sample chamber contained BSA 
or only buffer. The concentration ofDS26 and TP, in the assay chamber, were decreased 
by 70% when PrPc was present in the sample chamber. No binding was observed for 
GN8 orDS15. 
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Figure 26. DS104 binds to PrPc. 
(A) Chemical structure ofDS104, a fluoresceinated derivative ofDS26. (B) Various 
concentrations ofDS104 were injected for 3 min over sensor surfaces on which 17,000 
RU ofPrPc had been previously captured by amine coupling. Sensorgrams show small 
molecule binding in resonance units (RUs). The data was fitted using a Langmuir 
equation (solid black line) and the Ko was calculated to be 4 uM. (C) The fluorescence 
emission spectra ofDS104. One JlM ofDS104 was excited at 480 nm and the emission 
spectrum was recorded. DS 104 has a maximal absorbance of 520 nm. 
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Figure 27. Validation of DS26 binding to PrPc by FP. 
(A) Noncompetitive FP binding assay with DS104 and PrP. Recombinant C-PrP (120-
230) at several concentrations was incubated for 1 hour with 1 nM DS 104 and the 
polarization values were recorded. There was an increase in the polarization of DS 104 
with increasing PrP concentration. The values were fitted using a single site receptor 
model (Graphpad Prism) generating a K0 of 4 uM. (B) Noncompetitive FP binding assay 
with DS104, Myoglobin, BSA, and PrP. DS104 bound to PrP, but not to Myoglobin or 
BSA. (C) Noncompetitive FP binding assay with DS104 and A~ oligomers. Binding 
was not detected between DS 104 and A~ oligomers at concentrations of the protein 
up to 100 JlM. (D) Competitive FP binding assay with DS104 and PrP. Five JlM of 
recombinant PrP was incubated with 1 nM ofDS104 and various concentrations ofDS5, 
DS26, DS40, DS102, and GN8. Binding ofDS5, DS26, and DS40 competed with 
DS 104 leading to a loss of polarized signal. The values were fitted using a single 
receptor site completive model (Graphpad Prism); in solution K 0 of7 JlM for DS5, 0.3 
JlM for DS26, and 18.3 JlM for DS40 were calculated. 
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Figure 28. DS26 acts as a pharmacological chaperone for PrPc. 
(A) The far-UV CD spectra ofPrP at 25 °C (black) and 95 °C (red). The dashed line 
represents the wavelength (220 run) where proteins were monitored for melting data. (B) 
Melting curves of moPrP (23-230) alone or with DS26. The curves represent the fraction 
of unfolded protein as measured at 220 run during melting. Tm values for PrP alone and 
PrP with DS26 were 66.8 and 68.9 °C, respectively. 
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Figure 29. DS26 inhibits binding of A~ oligomers to PrPc measured by SPR. 
(A) Binding of A~ oligomers following an injection ofDS26. Various concentrations of 
DS26 were injected for 300 seconds over an SPR surface with immunocaptured full-
length PrP. After a PBST wash, 1 uM of A~ oligomers was injected; binding is measured 
in resonance units (RU). DS26 decreased the binding of A~ oligomers in a dose-
dependent manner. (B) Binding of A~ oligomers to PrP. One uM of A~ oligomers was 
passed over chip surfaces with immunocaptured full length PrP, N-PrP, or C-PrP and 
binding was measured in resonance units (RU). A~ oligomers bound to full length PrP 
and N-PrP, but did not bind to C-PrP. (C) Binding ofDS26 to PrP. Fifty uM ofDS26 
was injected over a surface containing full length PrP, N-PrP, or C-PrP, immobilized to 
the chip by amine coupling; binding was measured in resonance units (RU). DS26 bound 
to full length PrP and C-PrP, but did not bind to N-PrP. (D) DS26 affects A~ oligomers 
binding to full length PrP, but not N-PrP. Fifty uM ofDS26 was injected for 300s over a 
SPR surface with immunocaptured full-length PrP or N-PrP. After a PBST wash, 1 uM 
of A~ oligomers was injected and binding measured in resonance units (RU). 
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Figure 30. DS26 inhibits binding of A(l oligomers to PrPc measured by ELISA. 
(A) Binding curve of A~ oligomers to PrPc immobilized on an ELISA plate. The KD was 
calculated to be 28 nM. (B) Inhibition of A~ oligomers by DS26. DS26 decreased 
binding of A~ (1 00 nM) oligomers in a dose-dependent marmer. The half maximal 
inhibitory concentration (IC5o) was 15 !J.M. (C) Pretreatment ofDS26 and treatment of 
DS26 during A~ oligomers incubation (1 00 nM) reduced binding of A~ oligomers to 
PrPc. Addition of DS26 after binding of A~ oligomers did not affect the amount of A~ 
oligomers captured by PrP. Samples were run in triplicate and error bars represent 
standard error of the mean. 
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Figure 31. Effect ofDS15 and DS26 on Trp fluorescence and folding ofPrPc. 
(A) The far-UV CD spectra of 10 f.LM PrP at 25 °C (black line) or in the presence of 50 
f.LM DS26 (red line). Binding ofDS26 did not alter the secondary structure ofPrP. (B) 
Trp excitation spectra of full length PrP alone (red line), and in the presence of 10 uM 
(blue line) and 100 uM (green line) DS26. DS26 quenched Trp fluorescence in a dose-
dependent manner. (C) Trp excitation spectra of full length PrP and DS 15 at 0, 10, and 
100 uM. DS15 did not alter Trp fluorescence. (D) Trp excitation spectra ofN-PrP (23-
111) and DS26 at 0, 10, and 100 uM. DS26 did not alter the Trp fluorescence. 
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Figure 32. DS26 promotes interaction between theN- and C-terminal ends ofPrPc. 
(A) Recombinant myc-tagged C-PrP (120-230) was incubated with or without DS26 and 
N-PrP (23-111). C-PrP was immunoprecipitated using anti-myc antibody, 4A6. N1 (23-
111) was immunoprecipitated with C-PrP (120-230) only in the presence ofDS26. (B) 
Ten uM ofN1 was injected over an SPR surface with immunocaptured C-PrP (120-230) 
following a 300 second injection of 100 11M DS26 or PBST. Only N1 bound to DS26-
treated C-PrP (blue line) and not to PBST treated C-PrP (red line). 
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Figure 33. DS26 binds to PrPACR. 
(A) DS26 binds to PrP~CR. DS26 at several concentrations (3.1-50 uM) was injected for 
3 min over sensor surfaces on which 17,000 RU of ~CR PrP had been previously 
captured by amine coupling. Sensorgrams show small molecule binding in resonance 
units (RUs). The data was fitted using a Langmuir equation and the Kn was calculated to 
be 0.9 uM. 
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Chapter 4: Conclusions 
4.1 Overview 
The primary findings of this thesis are a) N1 can bind and prevent the toxicity of A~ 
oligomers and b) DS26 is a high affinity ligand of PrP that can inhibit the binding of A~ 
oligomers and PrP. 
N1 is a naturally occurring alpha cleavage fragment of the cellular prion protein. 
This fragment contains the two A~ oligomer binding sites on PrP. We demonstrated 
using immunoprecipitation and surface plasmon resonance (SPR) that that N1 fragment 
fully retains the ability to bind A~ oligomers, while the entire C-terminal half of PrPc is 
dispensable. We show that N1 binds selectively to transient A~ intermediates formed 
during the polymerization and amyloid fibril formation and inhibits further aggregation. 
We also report that the binding capacity ofN1 for A~ oligomers is influenced by at least 
two factors: 1) positively charged residues in the two A~-binding sites (23-31 and 95-
105), and 2) the distance between the two sites. Finally, we demonstrate that N1 is a 
potent inhibitor of A~ toxicity, based on its ability to prevent the detrimental effects of 
A~ oligomers in cultured hippocampal neurons, C. elegans, and mice. 
DS26 is an inositol like small molecule. DS26 was identified using an in silica 
screen to identify high affinity ligands to drug binding pockets on PrP. We show using 
SPR that a single isomer ofDS26 binds to PrP with sub-micromolar affinity. This 
binding is characterized by a slow multi -step dissociation. We confirmed the binding to 
PrP using equilibrium dialysis and fluorescent polarization (FP) with DS 104, a 
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fluorescein conjugated derivative ofDS26. We demonstrate using SPR and an ELISA 
that the binding of DS26 to PrP on the C-terminal inhibits the interaction of A~ oligomers 
with theN-terminal. The binding ofDS26 prevents A~-dependent suppression ofLTP in 
hippocampal slices. We also report the mechanism of DS26 action. The binding of DS26 
promotes an interaction ofthe flexible N-terminal with the globular C-terminal ofPrP. 
This interaction was confirmed using IP and SPR. Additionally, using tryptophan 
fluorescence we observe a change in theN-terminus ofPrP following DS26 binding. 
These results suggest that DS26 operates by an unusual allosteric mechanism in which 
ligand binding to a site in the structured C-terminal half of PrPc induces an 
intramolecular interaction with theN-terminal tail , thereby preventing A~ binding. 
4.2 PrPc has a dual role in AD 
Our data demonstrates that: a) the binding ofNl to A~ oligomers inhibits the 
toxicity of A~ oligomers and b) binding of A~ oligomers to PrPc can lead to synaptic 
dysfunction. These data suggests a possible model of PrPc function, in which PrPc could 
have two separate and distinct roles in AD: neurodegenerative and neuroprotective. The 
switch between these two pathways is based on the cleavage ofPrPc. In the 
neurodegenerative pathway, full length PrPc acts as an extracellular receptor for soluble 
A~ oligomers. The formation of the A~ oligomer- PrPc complex then transduces a toxic 
signal by activating Fyn, which leads to tau hyperphosphorylation, NMDA receptor 
reorganization, and synaptic dysfunction. In the neuroprotective pathway, full-length 
PrPc is cleaved by alpha secretase into soluble Nl and membrane bound Cl. The Cl 
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fragment is incapable of interacting with A~ oligomers and cannot start a toxic signaling 
cascade. The soluble N1 fragment neutralizes the toxic activity of A~. Additionally, 
alpha-secretase enzymes ADAM 10 and ADAM17, the proteases responsible for 
producing the N1- C1 fragments, cleave APP preventing the release ofthe A~ peptide, 
further reducing the amount of A~ oligomers (Figure 34). 
The role of alpha-secretase in the PrP our neuroprotective model, suggests that 
pharmacologically increasing the production ofN1 could be beneficial in AD. Studies 
have shown that the release ofN1 by alpha cleavage ofPrPc is enhanced by activation of 
protein kinase C (PKC) [170]. Interestingly, studies have tied PKC to memory 
formation [213] , and PKC has been found to be defective in AD patients [214]. PKC is 
involved inK+ channel function and also regulates the processing of APP [215, 216] 
suggesting the protein plays at least two roles in AD. In an AD mice model, a synthetic 
PKC activator, bryostatin-1, increased the amount of nonamyloidgenic APP processing, 
reducing A~ levels in the brain, and reduced premature death[217] . PKC activators could 
play a double role in AD by promoting the cleavage of APP and PrPc. This dual 
cleavage would reduce the number of extracellular PrPc receptors for A~ oligomers, 
reduce the amount of A~ released from APP, and increase the secretion of the N1 
fragment that binds disruptive A~ oligomers. 
To examine the neuroprotective role ofN1 in AD, further studies should identify 
if the N1-A~ oligomer binding interaction that we describe in vitro takes place in cell, 
animal models, or AD patients. In these studies, experiments could use a C-terminal 
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specific PrP antibody to clear the soluble brain fraction or CSF samples, 
immunoprecipitate with aN-terminal specific PrP antibody, and then immunoblot for A~ 
to measure the amount of A~ oligomers bound to N1. Additional studies could examine 
if the expression ofN1 alone (see Appendix A) in mice rescues the AD phenotype. 
4.3 Nl as a therapeutic. 
We have shown that N1 can bind select species of AD oligomers. We have also 
demonstrated that the binding ofN1 to AD oligomers inhibits the toxicity of AD 
oligomers in hippocampal neurons, C. elegans, and mice. These data suggests that N1 
binds to the toxic species of AD oligomers. Several studies have suggested that dimers 
[34], trimers [35], A~* 56 [30], and higher molecular weight oligomeric species [34] are 
the toxic conformation of AD oligomers. Biochemical and biophysical experiments such 
as size exclusion chromatography, fluorescence polarization, and analytical 
ultracentrifugation could characterize the complex formed by A~ oligomers and the N1 
fragment. These data could provide important insights regarding the oligomerization 
pathway and the structure of toxic A~ oligomers, laying the groundwork for the rational 
design of anti-AD therapeutics. Additionally, the affinity ofN1 for A~ oligomers is 
similar to that of an antibody [133]. This suggests that the N1 fragment could also be 
used for the isolation of toxic A~ species from biological samples, such as plasma or 
CSF, or be used in the quantitation of the amount of toxic species in clinical samples. 
Soluble A~ oligomers represent a primary pharmacological target for reducing 
synaptic dysfunction and cognitive decline in AD [168]. For example, anti-A~ antibodies 
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have been extensively tested in animal models and human patients. Our data indicate that 
the development ofN1-based compounds may represent a novel pharmacological 
approach for treatment of AD. Future studies could improve the affinity for AB 
oligomers and fine-tune the size of the species that the N1-based peptide interacts with. 
This could be accomplished by cloning the AB oligomer binding sites from N1 onto a 
dendrimeric scaffold as described by Chafekar et al [218]. Additionally, the peptide could 
be synthesized as retro-inversed to reduce degradation [219] and have a HIV TAT 
transduction domain [220] to to allow the peptide to cross the blood brain barrier (BBB). 
Compared to traditional anti-AB antibodies, a peptide based off ofN1 would be 
significantly smaller in size and be produced synthetically without the need of biological 
protein expression systems. These features could save on manufacturing costs. As an 
additional advantage, these N1 based peptides would only recognize soluble AB 
oligomers, not monomers or cell expressed full length APP. These features would allow 
our peptide to only bind the toxic species of AB, and not be depleted in the brain by non-
toxic forms. 
4.4 DS26 as a therapeutic. 
In our study, we have identified DS26, a high affinity ligand for PrPc. We have 
shown that DS26 binding to the PBD-1 pocket in the structured C-terminal half of PrPc 
inhibited the binding of AB to theN-terminus ofPrPc. In addition to blocking the binding 
of AB to PrPc, DS26 reduced the binding of AB to cells, and blocked the synaptic 
dysfunction of AB oligomers in brain slices. Our results with DS26 provide two 
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important scientific contributions: a) DS26 pharmacologically confirms the role ofPrP in 
AD and b) DS26 demonstrates that small molecules targeting PBD-1 can modulate the 
interaction between PrPc and A~. Further studies will determine if the other DS26 
derivatives that bind to PrPc (DS5, DS40, DS86) also inhibit A~ oligomers from binding. 
The data from the other derivatives could suggest a role of certain chemical features of 
PBD-1ligands to modulate the interaction of theN-terminus to the C-terminus ofPrPc 
and will provide insight for developing future DS26 compounds. 
However, the pharmacological properties ofDS26 most likely prevent its further 
development for therapeutic use. The hydrophilic nature of DS26 violates Lipinksi' s 
Rule of 5 making it unlikely to enter cells or pass the BBB [202-204]. This prediction 
was confirmed in our animal pharmacokinetic and pharmacodynamics (PK/PD) models 
in which we were unable to detect penetration of DS26 into the brain from an oral dose. 
Future studies will have to extensively modify DS26 to make a more suitable PBD-1 
ligand. 
As an alternative approach, further studies could use a DS26 derivative to screen 
for a new ligand for PBD-1. We have shown that our fluoresceinated DS26 derivative, 
DS104 binds to the same pocket as DS26. We could use DS104 in a competitive 
fluorescent polarization assay to screen for new ligands of PBD-1. In this assay, DS 104 
would be incubated with recombinant PrPc. The DS104 bound to the PBD-1 pocket on 
PrPc would be highly polarized in fluorescent spectroscopy measurements. A small 
molecule that bound to PBD-1 would compete with DS 104 and release free DS 1 04 from 
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the protein complex. This would be detectable as a large decrease in polarization 
fluorescence. This system can be readily scaled to high throughput screening. An ideal 
small molecule ligand for PBD-1 would have a high affinity for PrPc, a slow dissociation, 
high oral bioavailability, a long half-life in biological systems, and penetrate the blood 
brain barrier. Such a molecule could provide important advances in AD researcher by 
being used in animals or with patients in clinical trials. 
Within the amyloid hypothesis, previous studies have attempted to reduce the 
effects ofthe AD by preventing the processing of A~ [49, 51-53], increasing the 
clearance of the A~ peptide [54-57], or block the aggregation of A~ [64]. 
PBD-1 ligands specifically interact with a toxic receptor for A~ oligomers and represents 
a unique approach to AD therapy. Using a small molecule to preventing the interaction 
of A~ oligomers and PrPc may be more feasible then clearing large plaque deposits of A~ 
that have developed by the time clinical symptoms appear in patients. Additionally, the 
normal function of PrPc is unknown, thus targeting the PBD-1 site on PrPc is less likely 
to have cause side effects compared to other compounds (e.g. secretase inhibitors) which 
act on molecular targets that perform other essential biological functions. 
4.5 Natural ligands for PrPc 
We have shown that DS26 binding to the PBD-1 pocket in the structured C-
terminal half of PrPc induces a conformational shift in PrPc to increase the affinity of the 
N-terminus for C-terminus. One explanation of this interaction is that it is an artifact of 
the synthetic ligand, DS26, binding. It is also conceivable that DS26 is related to natural 
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ligands that bind to the PBD-1 domain and play an important role in prion biology. 
Further studies using the DS 104 competitive fluorescent polarization screen (described in 
section 4.3) could identify a natural ligand to PBD-1 on PrPc. Discovery of a natural 
chemical ligand to PrPc could help link PrPc to a specific cell signalling pathway. 
Further studies will be needed to confirm that exact nature of the conformational 
change in PrP after ligand binding to PBD-1. Studies using Fluorescence resonance 
energy transfer (FRET) or double electron-electron resonance (DEER) spectroscopy, 
with labels placed on the N and C terminus could demonstrate the interaction of specific 
residues on theN-terminus with residues on the C-terminus. Additional studies could be 
done by cross-linking the PrPc after ligand binding and using trypsin digests with mass 
spectroscopy to identify the regions where the N and C terminus interact. Experiments 
with NMR or X-ray crystallography would provide direct evidence of the exact ligand 
pocket on PrP for DS26. This information would confirm the PBD-1 site, give the exact 
residues involved in ligand, and demonstrate how those residues interact with theN-
terminus. 
In our model, binding of natural ligands to PBD-1 could act as a switch between 
allowing theN-terminal regions to interact with the extracellular environment and 
sequestering N-terminal and blocking its function. TheN-terminus ofPrPc is believed to 
be involved in many activities including binding to glycosaminoglycans, translocation of 
peptides across the plasma membrane, targeting PrPc to lipid rafts, metal binding, 
binding toxic oligomers, and binding the infectious form ofPrPc, PrP8c. Additionally, the 
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N-terminus is required for clathrin-mediated endoycytosis. PBD-lligands might exert 
control over the natural function of PrPc by altering its distribution on the plasma 
membrane. (Figure 35). 
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Figure 34. PrPc has both a neuroprotective and neurodegenerative role in AD. 
In our model, PrPc is involved in two pathways: neurodegenerative and neuroprotective. 
In the neurodegenerative pathway, APP undergoes beta/gamma cleavage releasing 
soluble A~ from the cell. The A~ peptide then undergoes oligomerization forming a 
heterogeneous mixture of soluble oligomers and amyloid plaques. Full-length membrane 
bound PrPc binds soluble A~ oligomers (shown as dashed arrows). This binding leads to 
Fyn activation, tau hyperphosphorylation, and synaptic dysfunction. In the 
neuroprotective pathway, alpha secretase cleaves PrPc releasing soluble Nl and 
membrane bound Cl (shown as solid arrows). The cleavage reduces the amount of full-
length PrPc receptors that could bind A~ oligomers. Soluble Nl binds A~ oligomers, 
prevents binding to PrPc, inhibits further oligomerization into fibrils, and may lead to 
clearance and degradation of A~ oligomers. Additionally, the active alpha-secretase 
cleaves APP preventing the release of A~, and further reducing the amount of A~ 
oligomers. 
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Figure 35. Ligands to PBD-1 could modulate PrPc function. 
In our model natural ligands to PBD-1 could act as a switch between an active and 
inactive N-terminus ofPrP. Binding ofDS26 was shown to promote the interaction of 
theN-terminus to the C-terminus. TheN-terminus ofPrPc is believed to be involved in 
many activities including: clathrin-mediated endoycytosis, binding to 
glycosaminoglycans, translocation of peptides across the plasma membrane, targeting to 
lipid rafts, metal binding, binding toxic oligomers, and binding the infectious form of 
PrPc, PrPsc. 
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Appendix A. Secretable Nl. 
Several neurodegenerative diseases have been linked to protein rnisfolding and 
aggregation. Examples include common diseases such as Alzheimer's disease (AD) and 
much less frequent disorders such as prion diseases. Oligomers of the A~ peptide, which 
is a cleavage product of the Alzheimer' s precursor protein (APP), are thought to be 
-
responsible for synaptic dysfimction seen in Alzheimer's disease [31]. Several recent 
studies have identified the cellular prion protein (PrPc) as a high affinity binding partner 
for A~ oligomers [99, 126, 130, 132, 133]. However, the functional relevance ofthis 
binding in AD is still unclear. Moreover, the binding has not been demonstrated under 
physiological conditions. 
Our research has recently focused on a naturally occurring, secreted cleavage 
product of the prion protein called PrP-N1 , which contains the two previously described 
binding sites for A~ oligomers. We tested whether the N1 fragment ofPrP was able to 
bind A~ oligomers by IP and SPR using synthetic PrP-Nl and A~. The results show that 
PrP-Nl is able to bind A~ oligomers with nanomolar affinity (See Chapter 2). 
We sought to address the physiological relevance of the PrP-Nl/A~ interaction by 
expressing these molecules in cells. However, we found that without the C-terminal 
region ofPrP, the expression ofN1 was extremely low (Figure 36). Several studies have 
suggested that the signal peptide on PrP is relatively inefficient; without a globular alpha 
helical C-terrninal end, PrP fails to enter the secretory pathway and is rapidly degraded 
[94, 95]. 
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In order to overcome this problem, we created several chimeric PrP-N1 proteins 
by utilizing different secretion signals (Table A-1) . Each construct was tested in 
HEK293 cells, and the expression and secretion ofPrP-N1 was detected either by 
Western blot (Figure 37) or immunofluorescent staining (Figure 38). We found that two 
secretion signals, the human a-1 anti-trypsin (hAAT) [221] and an in silica designed 
sequence (HMM38) [222], were both able to significantly increase the amount ofPrP-N1 
released into the medium (Figure 39). 
Constructs that promote secretion ofPrP-Nl make it possible to utilize cell-based 
systems and animal models to test whether PrP-N1 functions as an extracellular ligand 
for A~ oligomers, and whether such binding may influence the production or clearance of 
AP oligomers. Our results could potentially expand the current understanding of the role 
ofPrP in Alzheimer's disease, and suggest a functional role for PrP-N1 as neuro-
protective against effects of A~ oligomers in AD. 
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Table 2. List of signal secretion sequences tested. 
Signal Peptide Size AASequence Reference 
(AA) 
hPrP 22 MANLGCWMLVLFVATWSDLG LC [89] 
Basement 19 MRA WIFFLLCLAGRALAAP [223] 
Membrane 
Protein 
Human 24 MPSSVSWGILLLAGLCCL VPVSLA [221] 
a-1 anti-trypsin 
Human 48 MQRVNMIMAESPGLITICLLGYLLSA [221] 
Coagulation ECTVFLDHENANKILNRPKR 
Factor IV 
Synthetic Signal 22 MWWRL WWLLLLLLLL WPMVWA [222] 
Peptide 
Cystatin S 20 MARPLCTLLLLMATLAGALA [222] 
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Figure 36. C-terminal deletions interfere with N-terminal processing and secretion 
ofPrPc. 
HEK293 cells were transiently transfected with the PCDNA3.1 vector containing (A) 
full-length mouse PrP, (B) mouse PrP~CR lacking the GPI anchor (~231-254), (C) PrP-
N1 (residues 1-111), and (D) the N1 fragment without a secretion signal (residues 23-
111). Secretion ofthe constructs was measured by comparing methanol-precipitated 
media (M) to cells lysed with lysis buffer (L). 
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Figure 37. The hAAT signal sequence enables secretion ofPrP-Nl. 
HEK293 cells were transiently transfected with the PCDNA3.1 vector containing (A) 
full-length mouse PrP, (B) mouse PrP~CR lacking the GPI anchor (~231-254), (C) 
hAAT-PrP-N1 (PrP residues 2-111 preceded by the hAAT signal sequence), and (D) 
HMM38-PrP-N1 (PrP residues 2-111 preceded by the HMM38 signal sequence). 
Secretion of the constructs was measured by comparing methanol-precipitated media (M) 
to cells lysed with lysis buffer (L). 
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Figure 38. Immunofluorescent staining of PrP C-terminal deletions. 
HEK293 cells were transiently transfected with the PCDNA3.1 vector containing full-
length mouse PrP, mouse PrP~CR lacking the GPI anchor (~231-254), PrP-Nl (residues 
1-111), or the Nl fragment without a secretion signal (residues 23-111). Cells were 
stained with anti-PrP antibody 6Dll (green), anti-giantin antibody to mark the Golgi 
[224] (red), or nuclear stain DAPI (4',6-diamidino-2-phenylindole) (blue). Samples were 
treated with PBST (A) or 0.1% Triton Xl 00 (B). 
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Figure 39. Immunofluorescent staining ofhAAT-PrP-Nl and HMM38-PrP-Nl 
constructs. 
HEK293 cells were transiently transfected with the PCDNA3 .1 vector containing hAA T-
PrP-Nl (PrP residues 2-111 preceded by the hAAT signal sequence) or HMM38-PrP-N1 
(PrP residues 2-111 preceded by the HMM38 signal sequence). Cells were stained with 
anti-PrP antibody 6D11 (green), anti-giantin antibody to mark the Golgi (red), or nuclear 
stain DAPI (4',6-diamidino-2-phenylindole) (blue). Samples were treated with PBST (A) 
or 0.1% Triton X1 00 (B). 
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Appendix B. Identification of DS262 binding site on PrPc 
Soluble oligomers of the amyloid-~ (A~) peptide, a cleavage product of the 
amyloid precursor protein, are primarily responsible for synaptic dysfunction in 
Alzheimer's disease (AD) [31]. The cellular prion protein (PrPc), a cell surface 
glycoprotein involved in transmissible spongiform encephalopathies, has been shown to 
bind A~ oligomers and transduce downstream synaptotoxic signaling [126]. Thus, PrPc 
may represent a novel therapeutic target for treatment of AD. Previously, we have 
described the identification of a high-affinity ligand for PrPc that blocks the neurotoxic 
effects of A~ oligomers in cell cultures and brain slices (See Chapter 3). The compound, 
DS26, exerts this activity by inducing a self-inhibitory change in PrPc which blocks 
interaction with A~ oligomers. These results provide the first example of an entirely new 
class of potential AD therapeutics directed against PrPc -mediated neurotoxic pathways, 
rather than formation or clearance of A~. 
A major question remains regarding DS26 and its ability to modulate the 
interaction between PrPc and A~ oligomers. Where does DS26 binding to PrPc occur? 
DS26 was identified using an in silica screen for small molecule ligands against PrP-
binding domain 1 (PBD-1 ). PBD-1 is the result of in silica analyses using SiteMap, a 
software that identifies drug-able pockets on proteins [189]. PBD-1 is defined by twelve, 
non-continuous residues (134-137, 150, 154, 155, 157-160,208,210, 213) (Figure 19B). 
So far, we have determined that DS26 binds to the C-terminus ofPrP (residues 120-230, 
Figure 29C), but we have not located the exact binding pocket. 
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We designed and performed an alanine screen in an attempt to further elucidate 
the residues involved in DS26 binding. Seven residues on PrP, L130, M134, P162, P158, 
H187, T191 , and P208, were visually selected on their proximity and orientation towards 
the three highest ranked SiteMap binding pockets (Figure 40). Residues M134, P158, 
and P208 are located within PBD-1. We were able to clone and express 5 out of 7 mutant 
(P158A, Y162A, H187A, T191A, and P208A) PrP C-terminal fragments . The L130A 
and M134A mutants did not express in BL21Star Ecoli. Correct a-helical folding in the 5 
expressed mutants was confirmed using CD (results not shown). The purified protein 
mutants and the wild-type mouse PrP (120-230) were immobilized on SPR chips, and 
binding ofDS26 to each protein was measured. We did not observe any significant 
binding differences between the mutants and wild-type PrP (Figure 41 and 42). These 
results suggest that the residues mutated do not have an essential role in the binding of 
DS26 to PrP. 
Next, we tried to identify the binding site ofDS26 on PrPc using an antibody 
screen. An epitope recognized by PrPc antibody, D18, includes several amino acids in 
the PBD-1 pocket, i.e. residues 132-156 which include the first a-helix of 145-155 [225]. 
Using SPR, we examined whether D18 could compete with D26 for binding to PBD-1. 
In SPR lanes that received a saturating pre-injection ofD18, we observed a significant 
decrease in the binding ofDS26 to recombinant PrP (120-230) as seen in Figure 43. This 
suggests that the epitope binding ofD18 occurs at 132-156 and is involved in the 
interaction with DS26. Interestingly, a recently published report has shown that similar 
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C-terminal recognition antibodies, such as ICSM18, block the binding of A~ oligomers to 
PrP [130]; ICSM binds to PrP residues 131-153 [226]. These data suggest that ligand 
interactions with the first helix play an important role in modulating the binding of A~ 
oligomers. 
Lastly, we used an unbiased approach to search for the binding site ofDS26. 
Using NMR and 13C-labeled recombinant mouse PrP (120-230), we collected 
heteronuclear single quantum coherence spectra (HSQC) while titrating the response of 
DS26. We were able to observe a shift of at least two residues that occurred in a dose 
dependent manner (Figure 44, red and blue squares). Using previously published spectra, 
we were able to assign one of the shifted peaks to M206. It was not possible to assign all 
of the residues on the HSQC spectra. Additional studies with higher concentrations of 
PrP, spin label derivatives ofDS26, stronger NMR magnets, or more sensitive probes 
will be needed for precise identification of the DS26 binding pocket and a clear 
understanding of the interaction between PrP and DS26. Characterization of the DS26 
binding site will not only confirm our in silica models, but may provide important 
information regarding the nature and function of the prion protein. 
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Figure 40. Sitemap analysis of PrPc. 
Structure ofPrPc (ribbin, PDB 1XYX) with top 3 sitemap identified drug-able pockets 
(colored mesh). PBD-1 is identified with green. Alanine substitutions, targeting each of 
the pockets, were chosen by visual inpsection. Mutated residues are identified in grey. 
(Image was generated at ftmap.bu.edu) 
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Figure 41. SPR analyses of DS26 binding to point mutants. 
Different concentrations of DS26 were injected for 3 min over sensor surfaces on which 
17,000 RU of each of the PrP mutants had been previously captured by amine coupling. 
Sensor grams show small molecule binding in resonance units (RU s ). The data were 
fitted using the Langmuir equation, modeling a simple bimolecular interaction. There 
were no substantial differences in binding of any mutant proteins to DS26. 
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Figure 42. Point mutations in PrP do not affect binding to DS26. 
I so affinity graphs showing dissociations of DS26 and PrP mutants. The diagonal lines 
represent regions with the same KD. No substantial differences in binding ofDS26 to any 
of the mutants were observed. 
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Figure 43. Anti-PrP antibody decreased binding ofDS26 to PrP. 
Lanes Al-A4 contained amine-coupled PrP (120-230). (A) Saturating amounts of D18 
were injected in lanes AI (red) and A2 (blue). Lanes A3 (green) and A4 (purple) were 
treated with PBST. (B) Two concentrations of DS26 were injected directly after the 
antibody addition. Lanes that had been exposed to D18 (AI, red; A2, blue) showed 
reduced binding ofDS26. 
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Figure 44. 1H-13C HSQC NMR spectra ofPrP with DS26. 
(A) Three hundred J.lM of 1H-13C labeled PrP (120-230) was incubated with increasing 
amounts ofDS26. Amounts ofDS26 are expressed as molar equivalents. (B) 
Enlargement of the red rectangle in (A). Residues were identified based on previously 
published spectra. (BMRB Database Entry 4641 [227]) 
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